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ABSTRACT 
Over the past two decades, a growing body of literature within health economics has provided 
evidence of the impact of fetal conditions on individual’s health and economic outcomes over the 
entire life course. This dissertation contributes to the field of health economics by investigating 
the effects of two distinct types of public policies, antimalarial interventions in sub-Saharan 
Africa and medical marijuana laws in the United States, on early-life health. 
Chapter 1 adds to the increased understanding of the impact of in utero exposure to large-
scale interventions to combat endemic diseases by examining the effects of antimalarial 
interventions aimed at preventing and controlling malaria in pregnancy on birth outcomes. Since 
the year 2000, a coordinated international effort against malaria has led to a significant scale-up 
of intervention coverage across sub-Saharan Africa. One of the objectives of this undertaking 
was to improve maternal and early-life health. This chapter investigates the effect of access to 
malaria prevention and control measures, including insecticide-treated nets, intermittent 
preventive treatment in pregnancy, indoor residual spraying, and artemisinin-based combination 
therapy, on birth weight. I exploit the geographic and time variation in the rollout of antimalarial 
interventions in sub-Saharan Africa across regions with different levels of initial malaria 
prevalence to analyze 277,245 live births in 22 countries from 2000 to 2013 in a continuous 
difference-in-differences estimation framework and find that the diffusion of intermittent 
preventive treatment among pregnant women contributed to the reduction of low birth weight 
incidence in sub-Saharan Africa. I do not find other antimalarial interventions to be associated 
with significant improvements in birth outcomes. 
 viii 
Chapter 2 provides an investigation focused on examining the impact of medical 
marijuana laws in the United States on birth outcomes. As of June 2017, medical marijuana laws 
which liberalize the cultivation, possession, and use of cannabis for allowable medical purposes 
have been adopted by 29 states and the District of Columbia. The expansion of state-level 
legislation allowing for medical marijuana use has fueled an ongoing debate regarding drug 
policy. Despite a growing interest in investigating and quantifying both direct and indirect effects 
of marijuana liberalization policies, little is known about how they affect early-life health. Using 
data on the entire universe of births in the U.S. between 1990 and 2013 and a difference-in-
differences research design, I find no evidence to support the hypothesis that medical marijuana 
laws have a negative impact on birth weight and gestation, however I also find that medical 
marijuana laws are associated with reductions in Apgar scores. 
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CHAPTER 1: 
ANTIMALARIAL INTERVENTIONS AND EARLY-LIFE HEALTH: 
EVIDENCE FROM SCALE-UP IN SUB-SAHARAN AFRICA 
 
1.1 INTRODUCTION 
A growing literature in health economics and related fields provides evidence of the nine months 
spent in utero as a critical period that affects individual’s health and economic outcomes over the 
entire life course. Numerous papers substantiate that intrauterine shocks can have significant, 
long-lasting consequences (Currie and Vogl, 2013, Almond and Currie, 2011a, 2011b, Currie, 
2011, Currie and Rossin-Slater, 2015 provide an overview of this literature). Indicators of 
neonatal health such as birth weight have been found to predict many future outcomes including 
earnings, employment, test scores, educational attainment, family formation, crime, as well as 
health outcomes of next generations. While much of this literature focuses on developed 
countries, most recent studies suggest that health in utero and in early life may be an even more 
significant determinant of adult outcomes in developing countries due to more frequent and more 
numerous health shocks as well as limited remedial capacity. At the same time, estimating the 
effects of fetal conditions on various outcomes may be particularly challenging in developing 
countries due to large mortality effects. To the extent that variation in later-life outcomes can be 
explained by early-life health, these findings offer additional justification for policies aimed at 
improving maternal and neonatal health. 
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In the economic literature, short- and long-run effects of fetal shocks have been examined 
in a variety of contexts. Numerous studies have used catastrophic events such as famines, natural 
disasters, nuclear accidents, armed conflict, or terrorist attacks as sources of variation in in utero 
conditions to study their effects on both health and non-health outcomes (e.g. Chen and Zhou, 
2007; Almond et al., 2010; Lindeboom et al., 2010; Torche, 2011; Simeonova, 2011; Currie and 
Rossin-Slater, 2013; Banerjee et al., 2007; Almond, Edlund and Palme, 2009; Black et al., 2014; 
Mansour and Rees, 2012; Lauderdale, 2006; Camacho, 2008; Currie and Schwandt, 2016). Other 
papers have investigated more moderate fetal shocks such as tax hikes, strikes, or Ramadan 
observance (e.g. Lien and Evans, 2005(a), 2005(b); Almond and Mazumder, 2011). A number of 
studies have focused on the effects of fetal and early-life disease exposure, including both 
endemic and non-endemic diseases in settings with both increases and decreases in incidence due 
to availability of new treatments, pandemics, or large-scale eradication campaigns (e.g. Almond, 
2006; Kelly, 2011; Venkataramani, 2012; Bhalotra and Venkataramani, 2011; Bleakley, 2007, 
2010; Cutler et al., 2010; Lucas, 2010; Barreca, 2010; Lucas and Wilson, 2013; Miguel and 
Kremer, 2004; Apouey et al., 2017). Many of these papers specifically explore the effect of fetal 
shocks on birth weight (e.g. Torche, 2011; Simeonova, 2011; Currie and Rossin-Slater, 2013; 
Lauderdale, 2006; Camacho, 2008; Lien and Evans, 2005(a), 2005(b); Mansour and Rees, 2012). 
Short- and long-run effects of malaria have been an important focus of the fetal origins 
literature. The dramatic scale-up of antimalarial interventions in Africa since the year 2000 has 
increased the importance of accurate estimations of the impact on malaria epidemiology and 
burden. Effects of malaria and antimalarial interventions have been previously studied by 
examining eradication campaigns in a difference-in-differences framework using variation in 
initial disease prevalence for identification (e.g. Bleakley, 2010; Cutler et al., 2010; Lucas, 2010; 
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Venkataramani, 2012). However, both duration and intensity of malaria control measures may 
have significant impact on the interpretation of the effects and may explain heterogeneous results 
across various geographical settings. Thus, the effects of more modest decreases in malaria 
incidence, such as those achieved in sub-Saharan Africa, likely differ from the effects of a 
sustained eradication of malaria. 
Several recent papers have investigated the effects of antimalarial interventions in sub-
Saharan Africa on mortality and fertility (Wilde et al., 2017), anemia (Apouey et al., 2017) and 
education (Kuecken et al., 2015). However, their impact on early life health has been studied 
less. 
The present study aims at contributing to the fetal origins literature – and specifically to 
the growing body of evidence of the effect of in utero exposure to large-scale interventions to 
combat endemic diseases – by examining the effects of antimalarial interventions aimed at 
preventing and controlling malaria in pregnancy on birth outcomes. Current knowledge on the 
nature and determinants of changing malaria endemicity in sub-Saharan Africa and the effects of 
control programs on various outcomes beyond simple measures of disease transmission risk and 
mortality remains weak (Eisele et al., 2012). In recent years, many comprehensive reviews have 
highlighted various aspects of the epidemiology and burden of malaria in pregnancy but few 
have evaluated malaria control effectiveness under routine conditions. A large number of 
randomized controlled trials in sub-Saharan Africa have demonstrated that malaria prevention in 
pregnancy through intermittent preventive treatment in pregnancy with sulfadoxine-
pyrimethamine (IPTp-SP) and insecticide treated bed nets (ITNs) significantly reduces the 
prevalence of low birth weight (LBW) by as much as 43% (Desai et al., 2007). However, the 
extent to which the protection observed in such trials can be replicated in the context of targeted 
 4 
campaigns or a routine health system is uncertain, as assessment of the effectiveness of malaria 
prevention in pregnancy under real-world conditions has been limited. 
Related to the present chapter, an epidemiological study by Eisele et al. (2012) analyzes 
26 national cross-sectional datasets and finds an association between the exposure to full malaria 
prevention in pregnancy through IPTp or ITNs and a 21% reduction in the likelihood of LBW in 
women in their first or second pregnancy, however concerns about whether this relationship is 
causal remain.1 This chapter tries to alleviate these limitations by taking advantage of geographic 
and time variation in malaria control coverage across regions with different starting (pre-
intervention) malaria endemicity in a continuous difference-in-differences estimation framework 
in order to investigate to what extent the improvements in birth outcomes are specifically 
attributable to antimalarial interventions. Identifying the effects of interventions in this 
framework would lend credence to a causal interpretation of earlier findings and, more broadly, 
contribute to the body of knowledge on the efficacy of interventions designed to help children 
reach their full potential. 
The outline of this chapter is as follows. Section 1.2 provides background on malaria 
control in Africa and an overview of empirical evidence on the effect of malaria in pregnancy 
and the benefits of antimalarial interventions. Section 1.3 presents the data and some descriptive 
statistics. Section 1.4 discusses the empirical strategy and the identification assumptions. The 
                                                            
1 Eisele et al. (2012) use the MatchIt procedure in R to match newborns by survey dataset and by their mother’s 
exposure to dichotomous observables, then use lme4 package in R to fit a logistic random-effects generalized linear 
model to assess the association between exposure to malaria prevention during pregnancy and birth outcomes, with 
the matching strata included as random effects. This identification strategy raises two concerns. First, the main 
malaria prevalence measure used in this chapter, PfPR among children aged two to ten in 2007, seems more likely to 
be an outcome. That is, it would seem reasonable to expect that regions with high ITN and IPTp use during the study 
period (2000–2010) would have a lower PfPR as a result of their high take-up levels, all else constant. Second, 
Eisele et al. match newborns on a number of variables which are associated with better access to malaria prevention 
and health status at birth, including those which are not determinants of birth outcomes but are likely outcome 
measures themselves, for example indicator for at least one neonatal tetanus vaccination. Thus, estimated effects 
may be biased. 
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main results, as well as the specification checks are reported in Section 1.5. Section 1.6 
concludes. 
 
1.2 BACKGROUND 
1.2.1 Malaria Control in Africa between 2000 and 2015 
Malaria remains one of the main public health problems in sub-Saharan Africa, where during 
2013, an estimated 128 million people were infected with Plasmodium falciparum, a malaria 
parasite, at any one time (WHO, 2014). The region continues to carry a disproportionately high 
share of the global malaria burden. According to the latest estimates from WHO, in 2015, sub-
Saharan Africa accounted for most global cases of malaria (188 million (88%) out of 214 million 
cases) and most malaria deaths (394,000 (90%) of 438,000 deaths) (WHO, 2015). 
Since the year 2000, international efforts to combat malaria in sub-Saharan Africa, 
largely driven by the Roll Back Malaria initiative and the broader development agenda around 
the United Nations Millennium Development Goals (MDGs), have achieved an approximately 
twentyfold increase in malaria financing. This enabled widespread, although highly uneven, 
scale-up of coverage of ITNs, indoor residual spraying (IRS), IPTp, and prompt treatment of 
clinical malaria cases with artemisinin-based combination therapy (ACT). 
Vector control is the primary means to prevent and reduce malaria transmission. It targets 
the mosquitoes capable of transmitting malaria parasites and has been shown to effectively 
reduce or interrupt malaria transmission when coverage is sufficiently high. The two core vector 
control measures are ITNs and IRS. ITNs provide personal protection from mosquito bites by 
forming a physical barrier over a person sleeping under them. ITNs reduce human-vector contact 
not only by physically excluding vector mosquitoes, but also by repelling them or killing them if 
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they land on the net. IRS is the most effective way to rapidly reduce malaria transmission. It kills 
the mosquito vector, remains effective for 3–6 months, depending on the insecticide formulation 
used and the type of surface on which it is sprayed, and requires at least 80% of houses in 
targeted areas to be sprayed for maximum effect. In 2014, an estimated 56% of the population in 
sub-Saharan Africa had access to an ITN, compared to less than 2% in 2000, and approximately 
6% of the population at risk of malaria in Africa lived in households protected by IRS. The 
estimated proportion of the population for whom any form of vector control had been made 
available in sub-Saharan Africa increased from 2% in 2000 to 59% in 2014 (WHO, 2015). 
Use of antimalarial drugs both for prevention and treatment is another important 
component of malaria control. Chemoprevention of malaria is based on the use of antimalarial 
drugs given in treatment doses at predefined intervals, particularly to pregnant women and 
children, and constitutes another important component of antimalarial interventions. In 2014, an 
estimated 52% of eligible pregnant women received at least one dose of IPTp, compared to less 
than 5% in 2003 (WHO, 2015). Adoption and implementation of chemoprevention in children 
has remained limited. The proportion of children aged under 5 years with Plasmodium 
falciparum malaria who were treated with an ACT is estimated to have increased from less than 
1% in 2005 to 16% in 2014 (WHO, 2015). 
While this massive rollout of prevention and treatment tools has not yet reached intended 
coverage, it has resulted in sizeable progress in malaria control. Bhatt et al. (2015) find that since 
2000, Plasmodium falciparum infection prevalence in endemic Africa halved, the incidence of 
clinical disease fell by 40% and approximately 663 million clinical cases have been averted. 
WHO estimates that since 2000, malaria mortality in the African Region rates have fallen by 
66% among all age groups, and by 71% among children under five (WHO, 2015). While it is 
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widely recognized that the effects of malaria and antimalarial interventions extend far beyond the 
direct measures of fatalities and disease occurrence, estimates of such effects outside of trials 
remain limited. 
 
1.2.2 Malaria in Pregnancy and Birth Outcomes 
A large body of medical and epidemiological literature documents the devastating effect of 
malaria in pregnancy on the newborn infant, although most of the estimates come from small 
randomized controlled trials (Eisele et al., 2012). In areas of high malaria transmission in Africa, 
the risk of LBW (conventionally defined as birth weight <2500 g) is estimated to approximately 
double if women have placental malaria, with the greatest effect in first births (2–7 times higher 
than other birth orders) (Desai et al., 2007). In sub-Saharan Africa, nearly 20% of LBW 
deliveries are thought to be attributable to malaria in pregnancy, which represents 35% of 
preventable LBW in women of all pregnancy orders. Malaria-attributable LBW is estimated to 
be responsible for between 62,000 and 363,000 infant deaths every year in Africa, or 3 to 17 
deaths per 1,000 live births. As many as 11.4% of neonatal deaths and 5.7% of all infant deaths 
in malaria-endemic areas of Africa may be caused by malaria-attributable LBW. This effect is 
greatest in first born infants at 17.6% of neonatal deaths and 9.8% of infant deaths. 
Numerous randomized controlled trials conducted in sub-Saharan Africa and other 
endemic regions have shown that IPTp and ITN usage are associated with reduced risk of LBW 
(Desai et al. (2007) provide a review of relevant studies). Informed by this epidemiological 
evidence, the World Health Organization (WHO) has developed specific recommendations for 
controlling malaria and its effects during pregnancy in areas of stable transmission. The 
recommended package of interventions includes promotion and use of ITNs, administration of 
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IPTp-SP, and appropriate case management through prompt and effective treatment of malaria in 
pregnant women (WHO, 2014). 
WHO recommends IPTp-SP in all areas with moderate to high malaria transmission in 
Africa, as part of antenatal care (ANC) services. Specifically, IPTp-SP is recommended for all 
pregnant women at each scheduled ANC visit starting as early as possible in the second trimester 
and until the time of delivery, provided that the doses are given at least one month apart (WHO, 
2014). WHO recommends a schedule of four ANC visits (WHO, 2015). While SP is supposed to 
be made available at ANC clinics, so that pregnant women have immediate access to IPTp-SP 
during routine care, data reported by National Malaria Control Programs and nationally 
representative household surveys indicate stark differences between the proportion of women 
attending ANC clinics (91% (median) in 2014) and the proportion receiving the first and 
subsequent doses of IPTp (first dose: 64% (median), second dose: 45% (median), third dose: 
21% (median)) in sub-Sahahran Africa. An estimated 15 million of the 28 million eligible 
pregnant women at risk did not receive a dose of IPTp (WHO, 2015). These differences verify 
missed opportunities to deliver IPTp during ANC visits. Similarly, while ITNs, which are 
recommended to be provided as early in pregnancy as possible and used throughout the entire 
pregnancy and the postpartum period, are distributed to pregnant women through ANC clinics 
using free distribution or a voucher system when available, the scale-up of ITNs has been uneven 
with sizeable gaps in coverage. 
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1.3 DATA CONSTRUCTION AND DESCRIPTIVE STATISTICS 
1.3.1 Demographic and Health Surveys 
The first data source for this study is the Demographic and Health Surveys (DHS), a data 
collection option within the DHS Program, a USAID-funded project implemented by ICF 
International. DHS are nationally representative household surveys that provide data on a broad 
range of monitoring and impact evaluation indicators within the scope of demography, health, 
and nutrition.2 
For this analysis, I use individual- and household-level data on malaria preventive 
behaviors, fertility and socio-demographic characteristics from the Household and the Individual 
Woman’s DHS Questionnaires. The Reproduction section of the DHS Woman’s Questionnaire 
contains detailed birth histories for all children born to women in the sample, including dates of 
birth. Additionally, the Pregnancy and Postnatal Care section provides supplementary 
information on the births that occurred in the last 5 years prior to the survey, along with birth 
weight (for children weighed at birth, as recorded from a health card or from recall) and size at 
birth (for all children in the sample, as reported subjectively by the respondent), as well as 
information on any ANC received during the last pregnancy that resulted in a live birth, 
including use of antimalarial drugs. Given the scope of available information, this chapter 
concentrates on the respondent’s last live birth within 5 years prior to the time of the survey. 
The outcomes of interest are (i) whether the child weighed less than 2,500 g at birth, (ii) 
whether the child was smaller than average in size at birth as reported subjectively by the 
respondent, (iii) whether the child was very small in size at birth as reported subjectively by the 
respondent, and (iv) the child’s birth weight in grams. In order to accurately estimate the impact 
of antimalarial interventions on LBW incidence, I use both the conventional definition of LBW 
                                                            
2 DHS datasets are available free of charge for registered users at http://dhsprogram.com/data/available-datasets.cfm. 
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based on the child’s weight at birth (< 2,500 g) as well as the subjectively reported categorical 
data on the size of the baby due to the fact that not all infants are weighed at birth. In the sample, 
only 51.6% of the babies were weighed at birth (143,131 out of 277,245). 
The DHS Questionnaires also contain information on the mother’s background, including 
level of education, as well as household characteristics, including type of residence (urban or 
rural), and household wealth quintile.3 
I use a total of 42 surveys from 22 sub-Saharan countries. Table 1.1 summarizes data 
sources. Table 1.2 presents an overview of the DHS surveys used in the analysis. 
 
1.3.2 Malaria Atlas Project 
The second data source for this study is the Malaria Atlas Project (MAP), a non-profit 
collaboration hosted within the Division of Mathematical, Physical, and Life Sciences (MPLS) at 
the University of Oxford and funded by the Wellcome Trust, the Bill and Melinda Gates 
Foundation, the Global Fund, and a number of smaller foundations.4 
MAP predicts the Plasmodium falciparum infection prevalence at different locations to 
provide estimates of malaria endemicity and presents these predictions in the form of maps. In 
particular, MAP relies on Bayesian model-based geostatistical approach to estimate the 
percentage of children between the ages of 2 and 10 with detectable levels of the Plasmodium 
falciparum parasite in the peripheral blood in a given region, or PfPR2–10, since this measure is 
associated with a plateau in the age-prevalence relationship and thus acts as a standardized 
                                                            
3 Using principal components analysis, DHS calculates a wealth index measure based on data on a household’s 
ownership of selected assets, such as televisions and bicycles; materials used for household construction; and types 
of water access and sanitation facilities. The wealth index places individual households on a continuous scale of 
relative wealth and is a composite measure of a household’s cumulative living standard. DHS then sorts all 
interviewed households into five wealth quintiles. 
 
4 MAP data is publicly available at www.map.ox.ac.uk. 
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comparison. PfPR2–10 is estimated as a function of nearby malariometric survey data – which are 
weighted in each prediction according to their spatial and temporal proximity – and of a rich set 
of special environmental covariates, including climatology surfaces interpolated from networks 
of meteorological stations and remotely sensed data from Earth observation satellites.5 
To identify populations at different levels of risk, I calculate average transmission 
intensity for each sub-country region and year using MAP data on PfPR. I obtain raster files 
from MAP containing predicted spatio-temporal cube of age-structured PfPR at 5×5 km 
resolution across all endemic African countries for each year from 2000 to 2015, overlay the 
regions boundaries, and calculate average values of PfPR2–10 for each sub-country region in the 
sample. In particular, I am interested in identifying the starting (pre-intervention) malaria 
intensity in each region as measured by PfPR2–10 in 2000. 
Figure 1.1 demonstrates the variation in the initial (pre-intervention) PfPR2–10 in 2000 
across the 22 countries included in the analysis, as well as the evolution of PfPR2–10 across time 
during the study period. 
In addition to generating disease intensity estimates, MAP combines household-level data 
on ITN use and access to ACTs from various surveys with national malaria control program data 
on ITN, ACT and IRS provision to develop time-series models of coverage of these interventions 
within each country. ITN coverage data has similar structure to that of PfPR2–10 and provides 
modelled values for usage of ITNs for the years 2000 – 2015 measured as the percentage of 
individuals who slept under an ITN on any given night for all African countries where 
Plasmodium falciparum malaria is endemic. IRS and ACT coverage are measured as the 
percentage of the population protected by IRS of insecticides and the percentage of cases of 
fever in under-5 year olds that were treated with ACT, respectively. Both IRS and ACT 
                                                            
5 Gething et al. (2011) provide details on the construction of PfPR2–10. 
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information is available for all years from 2000 to 2015 for all African countries where 
Plasmodium falciparum malaria is endemic, however there is only a single value for each 
country in each year. 
MAP does not provide data on IPTp coverage, thus I use DHS Women’s Questionnaires 
to identify infants whose mothers reported receiving at least one dose of IPT during their last 
pregnancy. 
Figure 1.2 displays trends in IPTp-SP and ITN usage during the study period.6 Figure 1.3 
demonstrates the evolution of IRS and ACT coverage.7 
 
1.3.3 Kiszewski et al., 2004 
The third data source for this study is Kiszewski et al., 2004. The authors derive a spatial index 
of the stability of malaria transmission based on species-specific vector bionomics, vegetation, 
altitude, monthly precipitation thresholds, and monthly temperature thresholds to determine 
vectorial capacity8. The resulting index is presented in the form of maps with the 0.5-degree cell 
resolution9 and examines potential transmission stability of malaria which is exogenous to public 
health interventions and economic conditions. 
This chapter uses (sub-country) regional average values of the Kiszewski malaria 
stability index as an alternative measure of malaria intensity in addition to PfPR2–10 in 2000. 
                                                            
6 Figures B1 and B2 in Appendix B show variation in region-level IPTp coverage and ITN use across countries in 
Sub-Saharan Africa in 2000–2013, respectively. 
 
7 Figures B3 and B4 in Appendix B show variation in country-level IRS and ACT coverage in Sub-Saharan Africa 
in 2000–2013, respectively. 
 
8 Vectorial capacity is generally defined as the rate (usually daily) at which a bloodsucking insect population 
generates new inoculations from a currently infectious case. It is the most important characteristic of vector species 
from the epidemiological perspective. Vectorial capacity is a measure of potential, rather than actual, rate of 
transmission, as it contains no parasitological information. 
 
9 0.5-degree cells resolution is approximately equivalent to 50 km grid. 
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While the Kiszewski malaria stability index is not a measure of disease intensity but rather of 
malaria suitability, in the absence of antimalarial interventions prior to 2000, this index is a 
plausibly strong proxy for malaria prevalence in the year 2000. 
 
1.3.4 Sample Restriction and Descriptive Statistics 
I consider all countries for which both DHS (standard and continuous) survey data and MAP 
PfPR2–10 files are available and restrict the sample to the live births which occurred from 2000 to 
2013. The effective sample data comprises 255 regions in 22 countries. Using region of 
residence of the household as the panel variable and year of birth as the time variable, I create a 
panel for the analysis conducted in this chapter. For some countries, the boundaries of some 
regions have changed between surveys conducted in different years. In these instances, I 
combine regions using maps provided in the public report of each survey to ensure consistency 
over time. 
Descriptive statistics are reported in Table 1.4. Column (1) describes all children in the 
dataset. The full sample includes both children weighed at birth and those who were not. For 
each of these children, I have data on their size at birth as reported subjectively by the 
respondent. 15.8% of children are reported to be smaller than average at birth, and 4.8% are 
reported to be of very small size at birth. Column (2) describes the subsample of children 
weighed at birth. For each of these children, I have information on their birth weight in grams. 
Average birth weight in this subsample is 3,227 grams, 9.2% of the children are of LBW (< 
2,500 g). Column (3) summarizes data on the children not weighed at birth. Comparison of 
columns (2) and (3) shows that children weighed at birth are different from those who were not 
in many ways. Children weighed at birth are more likely to be born in urban areas (43.3% vs. 
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15.9%), wealthier households (3.3 vs. 2.4 average wealth quintile), and to educated mothers 
(35.8% vs. 22.8% for primary education and 33.5% vs. 10.9% for at least secondary education) 
and mothers who were more likely to follow the ANC recommendations (63.6% vs. 38.2% 
reported four or more ANC visits). 
The observational unit for this analysis is a live birth. In the analysis, I use both the 
subsample of children weighed at birth as well as the full sample of all children, as the former 
may not be representative of the general population. The total number of observations used is 
277,245 including 143,131 children weighed at birth. 
 
1.4 RESEARCH STRATEGY 
The goal of this chapter is to assess the effects of malaria control measures on birth outcomes by 
performing a reduced form linear estimation of a health production function in which 
antimalarial interventions are the inputs of primary interest. A simple model is presented in the 
Appendix A. The key idea of the model is that malaria preventive behaviors in pregnancy affect 
maternal health, which in turn affects infant health, however the sign of this indirect effect of 
malaria prevention on infant health status is ambiguous. While those pregnancies which would 
have ended in a live birth with or without malaria prevention, would have benefitted from the 
interventions and resulted in healthier children, the pregnancies that would have ended in a 
miscarriage in the absence of antimalarial interventions, may now have resulted in a live birth, 
albeit the child health status may have been poor. Thus, estimating the parameters of the health 
production function is necessary for predicting and assessing effects of public policies. To do 
this, I exploit the geographic and time variation in the rollout of antimalarial interventions in sub-
Saharan Africa across regions with different levels of initial malaria prevalence in a continuous 
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difference-in-differences estimation framework. The key intuition behind the empirical strategy 
is that benefits of antimalarial interventions likely differ across regions with different starting 
(pre-intervention) malaria endemicity as well as with the degree of malaria control coverage. 
The first source of variation in the data comes from the pre-intervention malaria 
endemicity, measured by PfPR2–10 in 2000, which ranges from 0.006 to 0.882, and the Kiszewski 
malaria stability index, which ranges from 0.000 to 34.314. Recent research documents that the 
individual as well as combined efficacy of interventions varies by setting and is contingent on 
many local factors, including vector ecology, health systems, and coverage levels (Bhatt et al., 
2015; Lim et al., 2011; Lengeler, 2004), as well as the extent of spatial externalities to 
intervention coverage (Gimnig et al., 2003). Thus, if effectiveness of IPTp, ITNs, IRS, and ACT 
in preventing malaria infections varies across regions with different transmission risk, it is 
plausible that improvements in birth outcomes will also vary with pre-intervention disease 
intensity. In this case, the non-malarious areas serve as a comparison group, filtering out 
common trends. 
The second source of variation in the data comes from the degree of the intervention 
coverage across different countries and sub-country regions. Prior to the introduction of MDGs 
in 2000, malaria control measures were extremely limited, and even after the start of antimalarial 
campaigns the depth of the distribution of IPTp and ITNs was not uniform across countries. For 
example, MAP estimates that, in 2012, only 15% of individuals in Nigeria slept under an ITN on 
any given night, whereas in Ghana, in same year over 44% of population slept under an ITN. I 
am most interested in the effects of the malaria control measures recommended to pregnant 
women: ITN use and IPTp. I additionally control for IRS and ACT usage at the country-year 
level. 
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To implement this empirical strategy, I follow an econometric approach most similar to 
that of as Apouey et al. (2017) and Wilde et al. (2017) in their analysis of anemia and mortality 
and fertility in sub-Saharan Africa, respectively.10 Specifically, for a child i who was born in 
country c, region r, month m, and year t, I estimate the following equation: !"#$%& = ( + *+,-./0-"#$%& + *1,-./0-"#$%&× 345$ − 345 +	*8,.9$&+	*:,.9$&× 345$ − 345 +	*;,<0#& +	*=,<0#&× 345$ − 345+	*>?@.#& +	*A?@.#&× 345$ − 345 + ΠC"#$%& + D& +	E$ +	F#%+ G#& + E$×HIJKL	 + M"#$%&, 
 
 
 
(1) 
where !"#$%& is the birth outcome (either a LBW indicator variable (1 if the child is of LBW, 0 
otherwise) or birth weight in grams), 345$ is the pre-intervention malaria endemicity, 345 is the 
average level of 345$  for all regions, ,-./0-"#$%& is an indicator for whether the mother of the 
child received IPT during the pregnancy, ,.9$&, ,<0#&, ?@.#& are the ITN usage, IRS and ACT 
coverage during pregnancy, respectively, and C"#$%& is a vector of individual controls: type of 
residence dummy (1 if urban, 0 if rural), household wealth quintile, maternal education variables 
(indicate whether the mother has primary or at least secondary education as compared to no 
education group), ANC utilization variables (indicate whether the mother visited an ANC facility 
at most 3 times or at least 4 times as compared to no ANC during pregnancy), mother’s age at 
birth, gender of the child (1 if male, 0 if female), firstborn indicator variable, birth spacing 
variable (1 if the preceding birth interval is under 24 months, 0 otherwise). Finally,	D& is a year 
fixed effect (to control for trends in outcomes across years in all countries), E$ is a region fixed 
effect (to control for permanent differences in outcomes across regions), F#% is a country-month 
                                                            
10 This approach is also similar in spirit to that used by Bleakley (2007, 2010), Fortson (2009, 2011), Lucas (2010, 
2013) and many others. 
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fixed effect (to control for seasonality of both malaria transmission risk and birth outcomes), G#& 
is a cohort (country-year) fixed effect (to control for country-specific trends in outcomes), E$×HIJKL is an interaction term between region-specific indicators and a yearly linear time trend 
(to control for differences in linear trends in outcomes across sub-country regions and relax the 
identification assumption of parallel trends between treatment and control groups) and M"$& is the 
disturbance. 
I estimate equation (1) using ordinary least squares11 and cluster the standard errors at the 
region level to allow for arbitrary correlation among observations in the same region over time. I 
am most interested in estimating the effects of IPTp and ITN coverage on birth outcomes. 
Because I demean 345$, I interpret the coefficients *+ and *8 as the average partial effect of 
IPTp-SP and ITN evaluated at the mean value of malaria prevalence instead of zero. 
Additionally, I am interested in the coefficients *1 and *:, since they measure the additional 
effects of IPTp-SP and ITNs in regions with levels of malaria endemicity that are different from 345. These coefficients can be interpreted as difference-in-differences estimators since even 
though all regions received antimalarial interventions and should have experienced 
improvements in birth weight outcomes, such improvements may have been different for regions 
with higher or lower malaria endemicity relative to those regions with close to the average level 
of malaria endemicity. 
For this empirical approach to be valid and able to identify the true effect of IPTp and 
ITN use during pregnancy on birth outcomes, the exposure to antimalarial interventions must be 
exogenous. If IPTp use is an individual or household-level decision, a potential concern is that 
                                                            
11 For ease of interpretation and to maintain consistency across specifications with continuous and binary dependent 
variables, all estimations are conducted using ordinary least squares. The results are not sensitive to changes in 
specification or alternative estimation procedures. Tables B1–B4 in Appendix B present results from alternative 
specifications. APE results obtained from probit models estimation (not reported) are also very similar. 
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mothers who receive IPTp doses during pregnancy are not comparable to mothers who do not 
receive IPTp doses during pregnancy, and therefore the potential birth outcomes of their children 
are likely quite different. If, for example, mothers who are less likely to have LBW children 
within a given region are also more likely to take-up preventative health treatments (like IPTp) 
when they become available in that region, then even with inclusion of cohort fixed effects and 
region fixed effects, the true causal effect of IPTp use will be confounded with the selection of 
"better" mothers into the take-up of IPTp. I try to alleviate these concerns by focusing on 
measures of access to the malaria control treatments, not the individual decisions to take IPTp or 
use ITNs. The ITN variable is the percentage of individuals who slept under an ITN on any given 
night during the 9 months prior to a given birth which I interpret as the likelihood that a given 
mother had access to a bed net during her pregnancy.12 The IPTp variable is an indicator for 
whether the mother of the child received IPT during the pregnancy at least once. According to 
published WHO reports, it is unusual that a woman declines IPTp at an ANC facility if it is 
available. Thiam et al. (2012) provide an overview of the evidence on the barriers for IPTp 
coverage in sub-Saharan Africa and conclude that individual level factors strongly associated 
with the use of IPTp are limited and adherence levels are high among women offered IPTp. I 
control for ANC attendance, which is highly correlated with receipt of IPTp, in order to 
disentangle the distinct effects of IPTp from those of ANC attendance, as the latter could 
plausibly reduce the incidence of LBW in other ways. 
The estimates identify the effects of antimalarial efforts even though malaria control 
officials may have targeted regions based on the pre-rollout level of malaria endemicity and poor 
                                                            
12 Under perfect circumstances, a better measure of access to ITNs would have been the percentage of individuals or 
households who received a net within a particular time period. While DHS surveys contain information on both bed 
net usage and ownership, these data are only available as of the time of the survey. Since this analysis focuses on the 
respondent’s last live birth within 5 years prior to the time of the survey, variables available through DHS are poor 
proxies of bed net usage or ownership at the time of the pregnancy. Malaria Atlas Project does not collect nor 
disseminate data on bed net provision or ownership. 
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birth outcomes in these regions because I control for both region fixed effects and the pre-rollout 
level of malaria endemicity. The key assumption in the identification strategy is that in the 
absence of the antimalarial interventions there were no changes in birth weight concurrent to the 
interventions and correlated with the malaria endemicity. This would be the case if, for example, 
infant birth weight was increasing the fastest in areas where malaria endemicity was the highest 
when there were no antimalarial campaigns. I conduct falsification checks (presented in Section 
5.2) to ensure that this unlikely scenario is not affecting the estimates. 
 
1.5 RESULTS 
1.5.1 Main Results 
The main results of the analysis are presented in Table 1.5. Informed by the epidemiological 
evidence of greater effectiveness of antimalarial interventions for first births (discussed in greater 
detail in sub-section 1.2.2), I conduct a subsample analysis for firstborn children only (columns 
(1) through (4)), in addition to estimating the effects for the full sample of children of all birth 
orders (columns (5) through (8)). In both samples, I use the subjectively reported measures of 
LBW for all children, as well as the conventional, objective measure of LBW based on birth 
weight in grams for children weighed at birth. 
In Table 1.5, the dependent variables are (i) whether the child was LBW (< 2,500 g) 
(columns (1) and (5)), (ii) whether the child was smaller than average in size at birth as reported 
subjectively by the respondent (columns (2) and (6)), (iii) whether the child was very small at 
birth as reported subjectively by the respondent (columns (3) and (7)), and (iv) birth weight in 
grams (columns (4) and (8)). In all specifications, I include a variety of socio-demographic 
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controls as explanatory variables, as well as control for cohort (country-year), country-month, 
and region fixed effects. 
In Table 1.5, the coefficients for IPTp-SP are always negative and statistically significant 
for all measures of LBW (columns (1) through (3) and (5) through (7)) with larger effects for 
firstborn children. In areas with average levels of malaria, firstborn infants of mother with access 
to IPTp-SP were 1.2 percentage points less likely to be LBW, 1.5 percentage points less likely to 
be small and 1.4 percentage points less likely to be very small (vs. 12.5%, 18.5% and 5.8% 
average, respectively). Thus, in areas with average initial malaria endemicity, access to IPTp-SP 
reduced the likelihood of LBW by 9.5%, of small births by 8.1%, and of very small births by 
24.1% for first births, all else equal. Children of all birth orders in areas with average initial 
malaria endemicity born to mothers who had access to IPTp-SP were on average 1.0 percentage 
point less likely to be LBW and 1.3 percentage points less likely to be small or very small (vs. 
9.2%, 15.8%, 4.8% average, respectively). Thus, in areas with average initial malaria 
endemicity, access to IPTp-SP reduced the likelihood of LBW by 10.9%, of small births by 
8.2%, of very small births by 27.1% for all birth orders, all else equal. These effects, while large 
in magnitude, are significantly more modest than those reported in epidemiological studies.13 
This is not surprising given that the goal of the present analysis is to estimate the average effect 
of provision of access to antimalarial interventions under routine conditions and not in a trial 
setting.14 
                                                            
13 McClure et al. (2013) provide an overview of published studies. For example, Desai et al. (2007) report that 
malaria prevention in pregnancy through IPTp-SP and ITNs significantly reduces the prevalence of LBW by as 
much as 43%. 
 
14 For example, Le Port et al. (2011) evaluated the efficiency of malaria prevention in pregnancy in a clinical trial 
setting in Benin, as well as subsequently, when the Benin government scaled-up the IPTp-SP program, and the 
results of the national scale-up were significantly more modest than in trials. 
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On the other hand, the effect of ITN usage at the average malaria endemicity has no clear 
pattern and is not statistically significant. A potential explanation is that I cannot measure 
whether a particular mother slept under an ITN during her pregnancy. I approximate this variable 
with the percentage of individuals in a given region during the 9 months preceding a given birth 
who reported sleeping under an ITN the night before the interview which may be a poor proxy 
for ITN availability. 
Finally, the socio-demographic controls have the expected signs and are usually 
statistically significant.15 For example, household wealth, mother’s education, male gender of the 
child, and receipt of ANC reduce the probability of LBW and of small or very small size of child 
at birth; while preceding birth interval of less than 24 months and first birth order increase the 
probability of poor birth outcomes. 
 
1.5.2 Robustness and Falsification Checks 
I re-estimate the main specification using an alternative measure of pre-intervention malaria 
intensity, Kiszewski malaria stability index. The results are presented in Table 1.6. 
The estimated effects of antimalarial interventions on birth outcomes are robust to the 
inclusion of the alternative malaria endemicity measure. Coefficients for IPTp-SP remain 
negative and statistically significant for all measures of LBW (columns (1) through (3) and (5) 
through (7)) and are nearly identical in magnitude to those obtained in the previous subsection. 
Notably, in columns (1) and (5) (dependent variable – indicator for whether the child weighed 
less than 2,500 g at birth) the coefficient on the interaction term of IPTp-SP and Kiszewski index 
is negative and statistically significant at the 5% level for all children and 1% level for firstborn 
                                                            
15 Table 1.5 reports the estimated coefficients for the main variables of interest only and thus omits the coefficients 
on the socio-demographic controls, which are instead shown in Tables B1–B4 in Appendix B. 
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children, suggesting that areas with higher levels of pre-intervention malaria endemicity had 
more to gain from malaria control. For the other outcomes of interest, the interaction terms of 
IPTp-SP and Kiszewski index are imprecisely estimated zeros, and the main coefficients on 
IPTp-SP are very similar to those obtained in the main results. 
I then conduct a series of specification checks to ensure that the results presented thus far 
are due to malaria control measures and not driven by other factors occurring at the same time as 
the antimalarial interventions. Given the main specification, any confounding effects would have 
to vary at the region-year level, as well as correlate with the level of malaria. For instance, it 
would be problematic if regions that would have experienced more rapid improvement in birth 
outcomes over the 2000s in the absence of any change in antimalarial behaviors were also more 
likely to receive and use IPTp-SP, ITNs, IRS, and ACT. This might have occurred if, for 
example, some regions were simply more likely to receive assistance to help them achieve any of 
the MDGs. In this case the regions where there was a larger increase in, for example, ITN 
availability (MDG 6) would also be the regions where more aid was targeted for decreasing early 
childhood mortality (MDG 4). 
First, I ask whether any nutritional changes concurrent with the availability of malaria 
preventive treatments and correlated with pre-intervention malaria endemicity may have 
contributed to the changes in birth outcomes estimated in Table 1.5. Since maternal caloric 
intake and nutritional stores are the sole source of fetal energy requirements, pre-pregnancy 
weight, gestational nutrition, and weight gain are important determinants of birth weight 
(Kramer, 1987). Select DHS surveys contain information on nutrition of mothers of children 
under 36 months. Specifically, the questionnaires ask whether the mother consumed particular 
foods and beverages in the day and night prior to survey. I re-run the main specification (1) using 
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the following indicators as dependent variables: whether the mother had any meat (such as beef, 
pork, lamb, goat, chicken, or duck), eggs, or potatoes. These foods are nutritionally rich and their 
consumption is highly correlated with caloric intake. Additionally, I re-estimate the main 
specification using mother’s body mass index (BMI) as a dependent variable. The results are 
reported in columns (1) – (4) of Table 1.7. I find that the availability of IPTp-SP, ITNs, IRS, and 
ACT did not have any statistically significant impact on maternal nutrition or BMI, thus I find no 
evidence of nutrition-related factors confounding the estimates. 
Second, I test whether the effects of antimalarial interventions on birth weight estimated 
in Table 1.5 may have been generated by other general welfare factors. I re-run the main 
specification using wealth and asset ownership indicators (dummies for electricity in household 
and ownership of a television) as dependent variables. The results are reported in columns (5) 
and (6) of Table 1.7. The effects of antimalarial interventions on the likelihood of living in an 
electrified household or owning a television are not statistically significant, which lends further 
credibility to the main analysis. 
 
1.5.3 Mortality Selection Effects 
The estimates of the effect of IPTp and ITN distribution on birth outcomes may be influenced by 
mortality selection effects. WHO estimates that even with a large growth in underlying 
population, the number of malaria deaths in children under 5 in the WHO African Region fell 
from 694,000 in 2000 to 292,000 in 2015 (WHO, 2015). If antimalarial interventions affected not 
only child mortality but also in utero mortality, this would lead to estimates that are smaller (less 
negative) than the true relationship and make the benefits of malaria prevention measures appear 
less pronounced. 
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For instance, in Table 1.5, the coefficients on the interaction terms of IPTp-SP and 
malaria prevalence are positive and statistically significant both for firstborns as well as for 
children of all birth orders for the very small size at birth outcome (columns (3) and (7)). It is 
plausible that the marginal fetuses who were more likely to die in utero in the absence of 
interventions in highly endemic areas, are now more likely to survive and be very small at birth 
due to availability of IPTp-SP. Furthermore, the coefficients on IPTp-SP for the birth weight 
outcome (columns (4) and (8)) are negative, although not statistically significant, while the 
coefficients on the interactions of IPTp-SP and malaria prevalence for the same outcomes are 
negative, significant, and large in magnitude. This suggests that antimalarial interventions may 
have affected the distribution of survivors. 
Ideally I would like to investigate whether regions with increasing IPTp/ITN use over the 
study period also saw decreases in in utero mortality. While DHS surveys contain some 
information on non-live births and miscarriages, I cannot distinguish such incidents from 
induced abortions in the data, as the DHS question asks “Have you ever had a pregnancy that 
miscarried, was aborted, or ended in a stillbirth?” Instead, to provide suggestive evidence on the 
magnitude of mortality selection, I estimate the effects separately for firstborn boys and firstborn 
girls. 
First pregnancies are associated with worse pregnancy outcomes, including greater 
likelihood of LBW and lower average birth weight, and are thus most likely to be affected by 
possible mortality effects (Kramer, 1987). Furthermore, while both male and female fetuses are 
negatively affected by malaria, the literature on "fragile males" has found male fetuses to be 
more vulnerable to detrimental conditions in utero than female fetuses (e.g. Kraemer, 2000; 
Eriksson et al., 2010; Almond and Mazumder, 2011; Currie and Schwandt, 2016; Dinkelman, 
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2017). While the heterogeneity of the effects of fetal shocks across genders can potentially also 
be explained by gender preference, I do not expect this to impact the results, as in sub-Saharan 
Africa behaviors reveal preference for variety or no preference (Rossi and Rouanet, 2015). 
Firstborn boys are, thus, likely to be affected the most by mortality selection, and evaluating the 
effects of antimalarial interventions using this subsample would yield the most conservative 
(lower bound) estimates. Similarly, non-firstborn girls are least likely to be affected by mortality 
selection and, therefore, the estimation of antimalarial interventions on this subsample would 
yield the upper bound for the estimates. 
The effects, estimated separately for firstborn boys and non-firstborn girls, are presented 
in Table 1.8. 
The estimates in Table 1.8 suggest that the effects of IPTp-SP for firstborn boys are 
slightly smaller in magnitude for measures of LBW (columns (1) through (3) and (5) through 
(7)) as well as for for birth weight in grams (columns (4) and (8)) (more negative, although not 
statistically significant) than those for non-firstborn girls. This is consistent with the “fragile 
males” hypothesis: if male fetuses are more vulnerable to the negative effects of malaria, 
availability of IPTp-SP increases their survival chances, while at the same time making the 
marginal survivor be born LBW. Thus, the overall effect of reduction in LBW incidence is 
smaller for boys than it is for girls. At the same time, the magnitude of the difference in 
coefficients across the two subsamples is very small, which suggests that the main analysis is not 
likely to be significantly impacted by mortality selection effects and thus provides accurate 
estimates of the average partial effects of antimalarial interventions. 
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1.6 DISCUSSION AND CONCLUSION 
Malaria control is one of the highest priorities on the international development agenda which is 
currently defined around two key policy initiatives for the 2016–2030 period: the Global 
Technical Strategy and Action and Investment to Defeat Malaria, led by WHO and the Roll Back 
Malaria Partnership. The primary goals comprise universal access to malaria prevention, 
diagnosis, and treatment, accelerated efforts towards elimination of malaria and attainment of 
malaria-free status, as well as transforming malaria surveillance into a core intervention. 
Estimates suggest that annual investments in malaria control and elimination will need to 
increase to US$ 6.4 billion per year by 2020, US$ 7.7 billion by 2025 and US$ 8.7 billion by 
2030 to meet these objectives (Bhatt et al., 2015). 
The effectiveness of insecticide-based vector control is threatened by malaria mosquitoes 
developing resistance to the insecticides used in ITNs and IRS. Similarly, antimalarial drug 
resistance has also been reported in various endemic countries. Despite the observed changes in 
parasite sensitivity, which manifest in the form of delayed parasite clearance, patients continue to 
respond to treatment, and long-lasting insecticidal nets remain effective (WHO, 2015). Analysis 
of progress provides means to monitor the success of international control efforts in achieving 
their goals and targets. Achievements of malaria interventions should be robustly evaluated to 
inform optimal policy strategy for the future. 
The present study aims to complement the existing literature on the effectiveness of 
specific malaria control measures by estimating the effect of provision of access to interventions 
(as opposed to adherence to recommendations with respect to treatments) in a real-world setting. 
I estimate that the availability of IPTp-SP has contributed to improvements in birth outcomes in 
sub-Saharan Africa and decreased the likelihood of LBW by 10.9% in areas with average initial 
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malaria prevalence, all else equal. The estimates provided in this chapter are much smaller in 
magnitude that those reported in numerous trials which find that malaria prevention in pregnancy 
through IPTp-SP and ITNs under the conditions of perfect provision and monitored compliance 
significantly reduces the prevalence of LBW by as much as 43% (Desai et al., 2007). These 
findings highlight the missed opportunities to deliver treatment and ensure proper adherence of 
those in need. 
This analysis is not without limitations. This study uses a reduced form approach rather 
than a structural model. The effects of antimalarial interventions on birth outcomes obtained in 
this chapter should be interpreted as intent-to-treat (ITT) estimates rather than the average 
treatment effect on the treated (ATET). Any geographic spillover effects of malaria control 
measures on neighboring regions are not captured in this analysis. This chapter does not consider 
potential longer-run child health outcomes which may plausibly be impacted by antimalarial 
interventions. 
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Figure 1.1: Malaria Endemicity in Sub-Saharan Africa, 2000–2013 
 
Notes: Top panel: estimated Plasmodium falciparum parasite rate in children between the ages of 2 and 10 in 2000. 
Bottom panel: estimated Plasmodium falciparum parasite rate in children between the ages of 2 and 10 from 2000 to 
2013. Underlying data from Malaria Atlas Project. 
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Figure 1.2: IPTp-SP Coverage and ITN Use in Sub-Saharan Africa, 2000–2013 
 
Notes: Top panel: proportion of pregnant women reporting receipt of at least one dose of intermittent preventive 
treatment in pregnancy with sulfadoxine-pyrimethamine (IPTp-SP). Bottom panel: estimated proportion of 
individuals who slept under an insecticide-treated bed net (ITN) on any given night. Underlying data from 
Demographic and Health Surveys (IPTp) and Malaria Atlas Project (ITN).  
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Figure 1.3: IRS and ACT Trends in Sub-Saharan Africa, 2000–2013 
 
Notes: Top panel: estimated proportion of the population protected by indoor residual spraying of insecticides. 
Bottom Panel: estimated proportion of cases of fever in under-5 year olds that were treated with artemisinin-based 
combination therapy. Underlying data from Malaria Atlas Project.   
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Figure 1.4: Birth Weight Trends in Sub-Saharan Africa, 2000–2013 
 
Notes: Top panel: average weight of infants at birth in grams from 2000 to 2013. Bottom panel: proportion of 
infants with birth weight below 2,500 grams. Underlying data from Demographic and Health Surveys. 
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Table 1.1: Summary of Data Sources 
 
Variables Definitions Sources and Years 
Dependent Variables 
Birth weight (g) Child’s birth weight in grams DHS, 2000–2013 
Low birth weight 1 if child weighed less than 2,500 g at birth, 0 
otherwise 
DHS, 2000–2013 
Small size at birth 1 if child was smaller than average in size at birth as 
reported subjectively by the respondent 
DHS, 2000–2013 
Very small size at birth 1 if child was very small in size at birth as reported 
subjectively by the respondent, 0 otherwise 
DHS, 2000–2013 
Malaria Endemicity 
PfPR2-10 in 2000 Plasmodium falciparum parasite rate among 
children two to ten in 2000 
MAP, 2000 
Kiszewski et al. (2004) malaria 
stability index 
Index of stability of malaria transmission Kiszewski et al., 2004 
Malaria Preventive Behaviors 
IPTp-SP: at least 1 dose 1 if mother of child received at least one dose of 
intermittent preventive treatment with sulfadoxine-
pyrimethamine during pregnancy, 0 otherwise 
DHS, 2000–2013 
ITN usage Share of individuals who slept under an insecticide-
treated net in a given region during a given 
pregnancy 
MAP, 2000–2013 
IRS coverage Share of individuals protected by indoor residual 
spraying of insecticides in a given country during a 
given pregnancy 
MAP, 2000–2013 
ACT coverage Share of cases of fever in under-5 year olds that 
were treated with artemisinin-based combination 
therapy in a given country during a given pregnancy 
MAP, 2000–2013 
Individual- and Household-Level Controls 
Household in urban area 1 if household is located in urban area, 0 otherwise DHS, 2000–2013 
Wealth quintile Household wealth quintile DHS, 2000–2013 
Mother has primary education 1 if mother has primary education, 0 otherwise DHS, 2000–2013 
Mother has at least secondary 
education 
1 if mother has at least secondary education, 0 
otherwise 
DHS, 2000–2013 
Mother’s age at birth Mother’s age at birth in full years DHS, 2000–2013 
ANC visits: at most 3 1 if mother received antenatal care between 1 and 3 
times during a given pregnancy, 0 otherwise 
DHS, 2000–2013 
ANC visits: 4 or more 1 if mother received antenatal care 4 or more times 
during a given pregnancy, 0 otherwise 
DHS, 2000–2013 
Male birth 1 if child is male, 0 otherwise DHS, 2000–2013 
Firstborn 1 if child’s birth order to the mother is one, 0 
otherwise 
DHS, 2000–2013 
Birth interval under 24 months 1 if preceding birth interval is under 24 months, 0 
otherwise 
DHS, 2000–2013 
 
Notes: DHS – Demographic and Health Surveys; MAP – Malaria Atlas Project; Kiszewski et al., 2004 – Kiszewski, 
A., Mellinger, A., Spielman, A., Malaney, P., Sachs, S. E., & Sachs, J. (2004). A global index representing the 
stability of malaria transmission. The American Journal of Tropical Medicine and Hygiene, 70(5), 486-498. 
  
 38 
Table 1.2: Demographic and Health Surveys Data Sources 
 
Country No. observations 
No. 
regions DHS Surveys 
Benin 17,672 12 DHS–2006, DHS–2011–12 
Burkina Faso 16,412 13 DHS–2003, DHS–2010 
Burundi 4,757 17 DHS–2010 
Cameroon 12,028 10 DHS–2004, DHS–2011 
Congo Brazzaville 7,405 11 DHS–2005, DHS–2011–12 
Congo Democratic Republic 15,746 9 DHS–2007, DHS–2013–14 
Ghana 7,284 10 DHS–2003, DHS–2008, DHS–2014 
Guinea 8,841 8 DHS–2005, DHS–2012 
Kenya 12,393 8 DHS–2003, DHS–2008–09, DHS–2014 
Malawi 17,667 27 DHS–2004–05, DHS–2010 
Mali 14,719 9 DHS–2006, DHS–2012–13 
Mozambique 6,971 11 DHS–2011 
Namibia 6,027 13 DHS–2006–07, DHS–2013 
Niger 12,839 8 DHS–2006, DHS–2012 
Nigeria 37,759 37 DHS–2003, DHS–2008, DHS–2013 
Rwanda 5,292 5 DHS–2005 
Senegal 22,536 11 DHS–2005, DHS–2010–11, DHS–2012–13, 
DHS–2014 
Sierra Leone 10,139 4 DHS–2008, DHS–2013 
Tanzania 10,523 9 DHS–2004–05, DHS–2010 
Uganda 9,374 4 DHS–2006, DHS–2011 
Zambia 12,806 9 DHS–2007, DHS–2013–14 
Zimbabwe 8,055 10 DHS–2005–06, DHS–2010–11 
    
Total: 22 countries 277,245 255 46 surveys 
 
Notes: DHS – Demographic and Health Surveys. 
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Table 1.3: Sample Breakdown by Year of Birth 
 
Year No. observations 
2000 4,520 
2001 8,381 
2002 14,912 
2003 19,188 
2004 21,810 
2005 20,073 
2006 19,777 
2007 18,429 
2008 23,658 
2009 27,437 
2010 32,961 
2011 27,758 
2012 24,094 
2013 14,247 
Total: 277,245 
 
Notes: This sample breakdown is for the Tables 1.5 and 1.6 regression samples. 
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Table 1.4: Descriptive Statistics 
 
 (1) (2) (3) 
 All children 
 
 
Mean 
(S. D.) 
Children weighed 
at birth 
 
Mean 
(S. D.) 
Children not 
weighed at birth 
 
Mean 
(S. D.) 
Birth weight (g) 
 
 3,226.557 
(701.333) 
 
Low birth weight (<2,500 g) 
 
 0.092 
(0.289) 
 
Small size at birth (smaller than average) 
 
0.158 
(0.365) 
0.132 
(0.338) 
0.185 
(0.389) 
Very small size at birth 0.048 
(0.214) 
0.035 
(0.185) 
0.062 
(0.240) 
PfPR2-10 in 2000 0.432 
(0.184) 
0.423 
(0.195) 
0.441 
0.171) 
Kiszewski malaria stability index 16.149 
(9.343) 
14.730 
(9.383) 
17.662 
(9.059) 
IPTp-SP: at least 1 dose 0.383 
(0.486) 
0.469 
(0.499) 
0.292 
(0.455) 
ITN usage 0.195 
(0.190) 
0.215 
(0.194) 
0.173 
(0.185) 
IRS coverage 0.050 
(0.103) 
0.064 
(0.117) 
0.034 
(0.083) 
ACT coverage 0.062 
(0.087) 
0.071 
(0.095) 
0.052 
(0.077) 
Household in urban area 0.300 
(0.458) 
0.433 
(0.495) 
0.159 
(0.366) 
Wealth quintile 2.864 
(1.400) 
3.310 
(1.387) 
2.390 
(1.249) 
Mother has primary education 0.324 
(0.468) 
0.358 
(0.479) 
0.288 
(0.453) 
Mother has at least secondary education 0.225 
(0.418) 
0.335 
(0.472) 
0.109 
(0.311) 
Mother’s age at birth 27.550 
(7.049) 
27.253 
(6.814) 
27.864 
(7.280) 
ANC visits: at most 3 0.354 
(0.478) 
0.347 
(0.476) 
0.361 
(0.480) 
ANC visits: 4 or more 0.513 
(0.500) 
0.636 
(0.481) 
0.382 
(0.486) 
Male birth 0.507 
(0.500) 
0.510 
(0.500) 
0.504 
(0.500) 
Firstborn 0.199 
(0.399) 
0.240 
(0.427) 
0.155 
(0.362) 
Birth interval under 24 months 0.127 
(0.333) 
0.108 
(0.311) 
0.147 
(0.354) 
    
Observations 277,245 143,131 134,389 
 
Notes: These summary statistics are for the Tables 1.5 and 1.6 regression samples. PfPR, ITN, IRS, and ACT 
information was drawn from the Malaria Atlas Project for the years 2000–2013. Kiszewski malaria stability index 
was drawn from Kiszewski et al., 2004. All other information was drawn from the 2003–2014 Demographic and 
Health Surveys (list of surveys used is presented in Table 1.2).
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Table 1.5: Estimated Effects of Antimalarial Interventions on Birth Outcomes 
 
 Firstborn children (columns 1 – 4) All children (columns 5 – 8) 
 (1) (2) (3) (4) (5) (6) (7) (8) 
VARIABLES LBW Small Very small Birth weight LBW Small Very small Birth weight 
         
IPTp-SP -0.012** -0.015*** -0.014*** -8.300 -0.010*** -0.013*** -0.013*** -5.096 
 (0.005) (0.005) (0.004) (10.996) (0.003) (0.003) (0.003) (6.524) 
IPTp-SP x Malaria prevalence (PfPR2-10) -0.019 -0.012 0.035* -80.951* 0.001 0.000 0.029** -79.315** 
 (0.024) (0.024) (0.019) (48.328) (0.014) (0.014) (0.013) (32.953) 
ITN 0.046 -0.017 -0.022 -194.098 0.022 -0.008 0.022 -115.455* 
 (0.064) (0.060) (0.037) (143.288) (0.024) (0.027) (0.016) (59.914) 
ITN x Malaria prevalence (PfPR2-10) -0.106 0.027 -0.192 258.671 -0.172 0.175 0.033 468.861* 
 (0.260) (0.244) (0.127) (551.461) (0.118) (0.145) (0.064) (267.334) 
IRS 0.090 -0.053 -0.061 -83.978 0.002 -0.014 0.014 191.530* 
 (0.105) (0.113) (0.056) (163.064) (0.044) (0.056) (0.020) (97.422) 
IRS x Malaria prevalence (PfPR2-10) 0.431* 0.394 0.182 -629.016 0.068 0.069 0.009 -320.276 
 (0.236) (0.271) (0.144) (459.901) (0.108) (0.144) (0.063) (264.232) 
ACT -0.005 0.105 0.118* -265.812 -0.009 -0.030 0.003 -181.241 
 (0.112) (0.104) (0.066) (283.810) (0.045) (0.046) (0.020) (121.337) 
ACT x Malaria prevalence (PfPR2-10) -0.345 -0.194 -0.057 1,009.177 -0.243 -0.189 0.020 745.234 
 (0.508) (0.473) (0.292) (871.488) (0.232) (0.228) (0.128) (500.163) 
         
Observations 34,318 55,051 55,051 34,318 143,131 277,245 277,245 143,131 
R-squared 0.049 0.060 0.055 0.089 0.029 0.052 0.043 0.081 
Controls Yes Yes Yes Yes Yes Yes Yes Yes 
Region FE Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes 
Country x Month FE Yes Yes Yes Yes Yes Yes Yes Yes 
Country x Year FE Yes Yes Yes Yes Yes Yes Yes Yes 
Region x Trend Yes Yes Yes Yes Yes Yes Yes Yes 
 
Notes: Controls included but not shown: indicator for household in urban area, wealth quintile, mother’s education dummies (primary education, at least 
secondary education), ANC dummies (at most 3 visits, 4 visits or more), mother’s age at birth, indicator for male birth, indicator for first birth, indicator for birth 
interval under 24 months. Robust standard errors are clustered at the region level, and are in parentheses below OLS coefficients. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10. 
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Table 1.6: Robustness Checks: Estimated Effects of Antimalarial Interventions on Birth Outcomes Using an Alternative 
Measure of Malaria Prevalence 
 
 Firstborn children (columns 1 – 4) All children (columns 5 – 8) 
 (1) (2) (3) (4) (5) (6) (7) (8) 
VARIABLES LBW Small Very small Birth weight LBW Small Very small Birth weight 
         
IPTp-SP -0.013*** -0.015*** -0.013*** -7.343 -0.010*** -0.013*** -0.012*** -5.916 
 (0.005) (0.005) (0.004) (10.929) (0.002) (0.003) (0.002) (6.529) 
IPTp-SP x Kiszewski index -0.002*** -0.000 -0.000 1.502 -0.001** 0.000 -0.000 0.506 
 (0.001) (0.001) (0.000) (1.151) (0.000) (0.000) (0.000) (0.625) 
ITN 0.031 -0.031 0.002 -167.369 0.021 -0.003 0.021 -92.047 
 (0.060) (0.058) (0.037) (140.969) (0.024) (0.024) (0.016) (59.026) 
ITN x Kiszewski index 0.001 0.002 0.003 -3.010 -0.004 0.002 0.002 1.833 
 (0.006) (0.005) (0.003) (8.931) (0.002) (0.002) (0.001) (4.285) 
IRS -0.034 -0.007 -0.129 163.260 -0.033 -0.081 -0.020 347.648* 
 (0.139) (0.137) (0.087) (284.009) (0.068) (0.081) (0.030) (183.513) 
IRS x Kiszewski index -0.007 0.012 -0.006 17.380 -0.003 -0.007 -0.004 13.449 
 (0.011) (0.011) (0.007) (24.746) (0.005) (0.007) (0.003) (15.449) 
ACT -0.030 0.134 0.128* -177.091 -0.033 -0.078 -0.013 -78.934 
 (0.148) (0.114) (0.074) (352.820) (0.058) (0.050) (0.023) (145.638) 
ACT x Kiszewski index -0.003 0.006 0.004 10.523 -0.005 -0.008* -0.002 14.951 
 (0.012) (0.009) (0.006) (24.724) (0.005) (0.004) (0.002) (11.308) 
         
Observations 34,318 55,051 55,051 34,318 143,131 277,245 277,245 143,131 
R-squared 0.049 0.060 0.055 0.089 0.029 0.052 0.043 0.081 
Controls Yes Yes Yes Yes Yes Yes Yes Yes 
Region FE Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes 
Country x Month FE Yes Yes Yes Yes Yes Yes Yes Yes 
Country x Year FE Yes Yes Yes Yes Yes Yes Yes Yes 
Region x Trend Yes Yes Yes Yes Yes Yes Yes Yes 
 
Notes: Controls included but not shown: indicator for household in urban area, wealth quintile, mother’s education dummies (primary education, at least 
secondary education), ANC dummies (at most 3 visits, 4 visits or more), mother’s age at birth, indicator for male birth, indicator for first birth, indicator for birth 
interval under 24 months. Robust standard errors are clustered at the region level, and are in parentheses below OLS coefficients. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10. 
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Table 1.7: Falsification Checks: Estimated Effects of Antimalarial Interventions on Nutrition and General Welfare 
 
 Nutritional factors (columns 1 – 4) General welfare factors (columns 5 – 6) 
 (1) (2) (3) (4) (5) (6) 
VARIABLES Meat Eggs Potatoes Mother’s BMI Electricity Television 
       
IPTp-SP 0.016 0.015 0.010 3.610 0.001 -0.004 
 (0.015) (0.010) (0.017) (4.521) (0.004) (0.004) 
IPTp-SP x Malaria prevalence -0.047 0.034 -0.093 28.460 -0.028 -0.008 
 (0.065) (0.056) (0.083) (22.713) (0.022) (0.021) 
ITN 0.064 -0.191 -0.489 -50.208 -0.048 -0.038 
 (0.436) (0.246) (0.407) (63.296) (0.055) (0.061) 
ITN x Malaria prevalence 1.583 1.897 0.677 90.141 -0.068 -0.019 
 (1.993) (1.174) (2.066) (246.959) (0.255) (0.211) 
IRS 1.505 1.233 -0.808 81.382 -0.041 0.035 
 (1.268) (0.902) (1.395) (106.581) (0.098) (0.089) 
IRS x Malaria prevalence 3.543 2.697 -2.066 288.384 0.133 -0.140 
 (3.148) (2.230) (3.445) (291.305) (0.236) (0.216) 
ACT 0.144 -0.113 0.004 -29.622 -0.079 -0.048 
 (0.376) (0.192) (0.372) (107.073) (0.090) (0.105) 
ACT x Malaria prevalence 0.045 -1.592 -1.062 -931.239* 0.421 -0.152 
 (2.422) (1.274) (2.282) (545.894) (0.453) (0.383) 
       
Observations 6,997 6,987 7,003 39,270 51,912 53,635 
R-squared 0.235 0.145 0.202 0.168 0.562 0.505 
Controls Yes Yes Yes Yes Yes Yes 
Region FE Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes 
Country x Month FE Yes Yes Yes Yes Yes Yes 
Country x Year FE Yes Yes Yes Yes Yes Yes 
Region x Trend Yes Yes Yes Yes Yes Yes 
 
Notes: Controls included but not shown: indicator for household in urban area, wealth quintile, mother’s education dummies (primary education, at least 
secondary education), ANC dummies (at most 3 visits, 4 visits or more), mother’s age at birth, indicator for male birth. Robust standard errors are clustered at the 
region level, and are in parentheses below OLS coefficients. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 1.8: Subsample Analysis: Estimated Effects of Antimalarial Interventions on Birth Outcomes of Firstborn Boys and 
Non-Firstborn Girls 
 
 Firstborn Boys (columns 1 – 4) Non-firstborn Girls (columns 5 – 8) 
 (1) (2) (3) (4) (5) (6) (7) (8) 
VARIABLES LBW Small Very small Birth weight LBW Small Very small Birth weight 
         
IPTp-SP -0.010* -0.014** -0.016*** -19.924 -0.012*** -0.011*** -0.010*** 2.812 
 (0.006) (0.006) (0.004) (16.365) (0.004) (0.004) (0.003) (10.407) 
IPTp-SP x Malaria prevalence -0.011 0.013 0.039** -96.850 -0.011 -0.013 0.024* -63.654 
 (0.027) (0.029) (0.019) (68.967) (0.020) (0.017) (0.014) (50.335) 
ITN -0.075 -0.079 -0.083** -88.427 0.023 -0.020 0.019 -178.768* 
 (0.073) (0.064) (0.038) (156.366) (0.045) (0.039) (0.025) (101.069) 
ITN x Malaria prevalence 0.100 0.109 0.092 -228.262 -0.315* 0.346* 0.122 646.595 
 (0.183) (0.184) (0.112) (358.676) (0.188) (0.184) (0.105) (447.805) 
IRS 0.048 -0.349** -0.104 498.486* 0.015 0.049 0.054 276.416* 
 (0.123) (0.146) (0.073) (273.536) (0.073) (0.087) (0.038) (163.668) 
IRS x Malaria prevalence 0.056 -0.179 -0.037 -166.657 -0.195 -0.009 -0.067 159.360 
 (0.315) (0.349) (0.173) (701.281) (0.201) (0.208) (0.104) (406.742) 
ACT -0.138 0.034 0.058 0.903 -0.058 -0.077 0.014 -31.677 
 (0.154) (0.139) (0.109) (387.021) (0.094) (0.076) (0.037) (201.651) 
ACT x Malaria prevalence -0.450 -0.079 -0.171 873.585 -0.336 -0.008 0.028 918.757 
 (0.369) (0.409) (0.238) (826.934) (0.388) (0.355) (0.211) (861.880) 
         
Observations 17,531 27,987 27,987 17,531 53,287 109,585 109,585 53,287 
R-squared 0.057 0.058 0.056 0.094 0.035 0.057 0.050 0.076 
Controls Yes Yes Yes Yes Yes Yes Yes Yes 
Country Year FE Yes Yes Yes Yes Yes Yes Yes Yes 
Country Month FE Yes Yes Yes Yes Yes Yes Yes Yes 
Region FE Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes 
 
Notes: Controls included but not shown: indicator for household in urban area, wealth quintile, mother’s education dummies (primary education, at least 
secondary education), ANC dummies (at most 3 visits, 4 visits or more), mother’s age at birth. Robust standard errors are clustered at the region level, and are in 
parentheses below OLS coefficients. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10. 
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CHAPTER 2: 
MEDICAL MARIJUANA LAWS AND EARLY-LIFE HEALTH 
 
2.1 INTRODUCTION 
Although possession and sale of marijuana for any purpose remain illegal at the U.S. federal 
level, as of June 2017, medical marijuana laws (MMLs) which liberalize the cultivation, 
possession, and use of cannabis for allowable medical purposes have been adopted by 29 states 
and the District of Columbia. With the expansion of state-level legislation allowing for medical 
marijuana use and the corresponding ongoing debate regarding drug policy, there has been a 
growing interest in investigating and quantifying both direct and indirect effects of the 
implementation of MMLs. 
Many recent studies have estimated the effects of MMLs on a variety of economic and 
public health outcomes including marijuana use among adults, alcohol consumption, tobacco 
use, hard drug use, prescription medication use, labor market outcomes, depression, body weight, 
health of older adults, and other measures and indicators (Anderson et al., 2013; Anderson et al., 
2014; Anderson et al., 2015; Bradford and Bradford, 2016; Choi et al., 2016; Chu, 2014; Chu, 
2016; Pacula et al., 2014; Sabia and Nguyen, 2016; Sabia et al., 2017, etc.). However, to date 
little is known about the effects of MMLs on early-life health. 
The effect of MMLs on early-life health is theoretically ambiguous. If MMLs allow 
pregnant women to effectively treat qualifying physical or mental conditions which would 
otherwise result in poor birth outcomes, MMLs could improve neonatal health indicators. If the 
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effects of MMLs spill over into the recreational market and increase non-medicinal marijuana 
use among pregnant women, MMLs could worsen birth outcomes. MMLs can also have an 
impact on birth outcomes through their effects on alcohol, tobacco, or other drugs, with the 
direction of the effect depending on whether marijuana and other risky behaviors are substitutes 
or complements. Furthermore, the effects of MMLs on birth outcomes may display significant 
heterogeneity by age, race, or other socio-demographic characteristics. 
Using restricted individual-level natality data (with geographic detail) from National 
Center for Health Statistics (NCHS) from 1990 to 2013 and taking advantage of the geographic 
and temporal variation in the implementation of MMLs, this chapter aims at estimating the 
effects of state-level marijuana legislation on early-life health, particularly birth outcomes, such 
as birth weight, length of gestation, and Apgar scores in a difference-in-differences framework. I 
find that while MMLs have no impact on birthweight or gestation, they are associated with 
decreases in Apgar scores and increased likelihood of severe distress and mild distress births. 
Analysis of both direct and indirect effects of MMLs provides means to monitor the 
success of public policy in achieving its goals and targets. The impact of MMLs should be 
robustly evaluated to inform optimal policy strategy for the future. This study provides new 
information to the current policy debate surrounding marijuana liberalization legislation. 
The outline of this chapter is as follows. Section 2.2 provides background on MMLs in 
the United States, an overview of prior economic literature, a discussion of potential mechanisms 
linking MMLs and birth outcomes, and a summary of the empirical evidence on the effect of 
marijuana use in pregnancy. Section 2.3 presents the data and some descriptive statistics. Section 
2.4 discusses the empirical strategy and the identification assumptions. Main results, robustness 
checks and subsample analysis are reported in Section 2.5. Section 2.6 concludes. 
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2.2 BACKGROUND 
2.2.1 Medical Marijuana Laws in the United States 
At the federal level, manufacture, importation, possession, use, and distribution of controlled 
substances is regulated by The Controlled Substances Act of 1970, a federal drug policy that 
categorizes drugs into five “Schedules” or classifications based on their potential for abuse, 
status in international treaties, any medical benefits they may provide, and safety. Marijuana 
remains classified as a Schedule I drug, which means that it is deemed to have “no currently 
acceptable medical use in treatment in the United States,” a high potential for abuse, and “a lack 
of accepted safety for use... under medical supervision” (O’Keefe, 2013). Other Schedule I drugs 
include heroin, ecstasy, and LSD. For comparison, cocaine and morphine are Schedule II drugs, 
Vicodin is a Schedule III drug, Ambien, Xanax, and Valium are Schedule IV drugs, and 
Robitussin is a Schedule V drug. 
Despite this, as of June 2017, MMLs which liberalize the cultivation, possession, and use 
of cannabis for allowable medical purposes have been adopted by 29 states and the District of 
Columbia. State laws differ in terms of the specific conditions and illnesses that are accepted for 
medical marijuana use. Frequently approved conditions include chronic pain, nausea, cachexia 
(weakening or wasting of the body), wasting syndrome resulting from HIV, glaucoma, AIDS, 
and cancer (Bradford and Bradford, 2016). States that legalized medical marijuana between 1990 
and 2013 are shown in Figure 2.1. Table 2.1 presents dates of passage of original legislation and 
effective dates of the state medical marijuana laws. 
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2.2.2 Prior Economic Studies on the Effects of Medical Marijuana Laws 
With the expansion of state-level legislation allowing for medical marijuana use and the 
corresponding ongoing debate regarding drug policy, there has been a growing interest in 
investigating and quantifying both direct and indirect effects of the implementation of MMLs. In 
particular, the effects of MMLs have been an actively researched topic within economic 
literature. 
Economic studies have investigated the effect of MMLs on prescription medication use 
(Bradford and Bradford, 2016), recreational marijuana use (Anderson et al., 2015; Pacula et al., 
2015; Wen et al., 2015; Chu, 2014), use of other substances, such as alcohol (Wen et al., 2015; 
Anderson et al., 2013), tobacco (Choi et al., 2016), and hard drugs (Wen et al., 2015; Chu, 2015), 
labor market outcomes, such as labor supply (Nicholas and Maclean, 2016), earnings (Sabia and 
Nguyen, 2016), and sickness absences (Ullman, 2016), health outcomes, such as body weight 
(Sabia et al., 2017), opioid addictions and opioid overdose deaths (Powell et al., 2015), suicides 
(Anderson et al., 2014), and traffic fatalities (Anderson et al., 2013), and even seatbelt use 
(Adams et al., 2017). Overall, these studies suggest that MMLs increase recreational use of 
marijuana among adults but not teenagers, decrease alcohol, tobacco, and heroin, but not cocaine 
use, decrease BMI, suicides, and traffic fatalities, and improve labor market outcomes for older 
adults. 
Despite a growing body of literature on the impact of MMLs, little is known about the 
effect of these laws on early-life health. 
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2.2.3 Mechanisms Linking Medical Marijuana Laws and Birth Outcomes 
The effect of MMLs on early-life health is theoretically ambiguous. If MMLs allow pregnant 
women to effectively treat qualifying physical or mental conditions which would otherwise result 
in poor birth outcomes, MMLs could improve them. MMLs could increase recreational 
marijuana use by increasing availability and access or by changing perceived harmfulness, as it 
can now be viewed as a medicine (Pacula et al., 2015). If the effects of MMLs spill over into the 
recreational market and increase non-medicinal marijuana use among pregnant women, MMLs 
could worsen birth outcomes. MMLs can also have an impact on birth outcomes through their 
effects on alcohol, tobacco, or other drugs, with the direction of the effect depending on whether 
marijuana and other risky behaviors are substitutes or complements. Furthermore, the effects of 
MMLs on birth outcomes may display significant heterogeneity by age, race, or other socio-
demographic characteristics. 
 
2.2.4 Marijuana Use and Birth Outcomes 
In the United States, marijuana is the most widely used drug during pregnancy with estimated 
usage rates varying from as low as 2% to as high as 11% (Chabarria et al., 2016) and continuing 
to increase (Brown et al., 2017). Despite a large volume of literature on the effects of marijuana 
use in pregnancy1, the results of the existing studies are conflicting, and a scientific consensus on 
the risks of marijuana has not been achieved. 
Given the passage of cannabinoids to the placenta, a link between marijuana use and 
adverse neonatal and later-life outcomes is biologically plausible. Marijuana is thought to affect 
glucose and insulin regulation and thus has a potential to affect fetal growth trajectory (Metz and 
                                                            
1 See Gunn et al. (2016) for a systematic review and meta-analysis and Metz and Stickrath (2015) for a clinician-
oriented review. 
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Stickrath, 2015). Furthermore, marijuana may affect fetal brain growth and neurodevelopment 
through its interaction with the endocannabinoid system (Volkow et al., 2017). Despite this, the 
evidence of the effects of marijuana use in pregnancy on various measures of infant health is 
mixed. While many studies find associations between maternal marijuana use and fetal growth 
restriction, preterm birth, increased placement in NICU/ICU, and other adverse neonatal 
outcomes, many others report no such associations, and some even find beneficial effects of 
prenatal marijuana use. Overall, the effects of cannabis on early-life outcomes remain largely 
unknown due to confounding factors such as tobacco, alcohol, and other drug exposure, as well 
as socio-demographic characteristics not considered by existing studies (Gunn et al., 2016). 
Given the uncertainty about the risks of marijuana use in pregnancy due to insufficient 
data and specifically citing the growing number of states legalizing marijuana for medicinal and 
recreational purposes as a concern, the American College of Obstetricians and Gynecologists 
(ACOG) recommends that pregnant women and women contemplating pregnancy be 
discouraged from using marijuana. Furthermore, ACOG discourages obstetrician-gynecologists 
from recommending the use of medical marijuana during preconception, pregnancy, and 
lactation and suggests that pregnant women or women contemplating pregnancy discontinue use 
of marijuana for medicinal purposes in favor of alternative therapies for which there are better 
pregnancy-specific safety data. (ACOG, 2015). 
 
2.3 DATA CONSTRUCTION AND DESCRIPTIVE STATISTICS 
2.3.1 NCHS Natality Data 
This chapter uses information on individual birth records from the Centers for Disease Control 
and Prevention’s National Center for Health Statistics’ (NCHS) U.S. Natality Files for years 
 51 
1990 – 2013. NCHS receives detailed information on all live births, prepared from individual 
records submitted by hospitals and processed by each registration area, through the Vital 
Statistics Cooperative Program.2 3 Birth data available in the U.S. Natality Files are based on 
100% of the birth certificates registered in the 50 States and the District of Columbia.4 5 Births to 
nonresidents of the United States are excluded from the analysis. Births occurring to U.S. 
citizens outside of the United States are not included in the Natality Files. 
Information on each birth contains detailed characteristics of the newborn, including time 
and place of birth, birth weight, gestation, Apgar score, plurality, abnormal conditions, and 
congenital anomalies, demographic characteristics of the mother, such as age, race, Hispanic 
origin, marital status, and education, along with medical and health information on the pregnancy 
and delivery. This data is obtained directly from the mother, as well as the medical records of the 
mother and infant.6 
                                                            
2 All states require birth certificates to be filed for all live births regardless of length of gestation or birth weight, and 
Federal law mandates national compilation and publication of births and other vital statistics data. If a delivery 
results in a fetus that shows no evidence of life (no heartbeat, respiration, voluntary movement of muscles, or any 
other evidence of life), a fetal death report is filed. 
 
3 All 50 U.S. states, the District of Columbia, the independent registration area of New York City, and U.S. 
territories (Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, and the Commonwealth of the Northern 
Mariana Islands) are considered registration areas for the purpose of collecting vital statistics data. 
 
4 More than 99% of births occurring in the United States are registered. For more information on completeness of 
registration, see user guides for the natality public use files, available at: 
https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm. 
 
5 While New York City is considered a distinct registration area, separate from the state of New York, for the 
purposes of this chapter, New York City births are merged with births that occurred in the rest of the New York 
state. U.S. territories data are available in a separate set of files and are not used in this chapter. 
 
6 Figures C1 and C2 in the Appendix contain images of the U.S. Standard Certificates of Birth revised and adopted 
in 1989 and 2003, respectively. Table C1 in the Appendix presents the timeline of the implementation of the 2003 
revision by the 50 U.S. states and the District of Columbia. While many data items are common to both 1989 and 
2003 standard birth certificates, several items were substantially modified, removed altogether, or introduced for the 
first time in the 2003 revision. This chapter uses only those data items which are directly comparable across the two 
standard birth certificates, as well as items which could be sufficiently harmonized. 
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U.S. Natality Files are publicly available at the official NCHS website,7 however, 
beginning with the 2005 data year, no longer include geographic detail. Restricted data files with 
geographic identifiers are available to researchers upon request following a review by the 
National Association for Public Health Statistics and Information Systems (NAPHSIS).8 
The primary outcomes of interest for this analysis are birth weight, gestation, and Apgar 
score. In order to capture the potential effect of MMLs on these outcomes along their 
distributions, I define the following outcome variables: 1) birth weight in grams; 2) indicator for 
extremely low birth weight (infant born weighing less than 1,000 grams); 3) indicator for very 
low birth weight (infant born weighing less than 1,500 grams); 4) indicator for low birth weight 
(infant born weighing less than 2,500 grams); 5) gestational age in weeks; 6) indicator for 
preterm birth (gestational age less than 37 weeks); 7) indicator for late preterm birth (gestational 
age greater than 34 weeks but less than 37 weeks); 8) indicator for early term birth (gestational 
age greater than 37 weeks but less than 39 weeks); 9) 5-minute Apgar score (Apgar score 
between 0 and 10); 10) indicator for severe distress at birth (Apgar score between 0 and 3); 11) 
indicator for mild distress at birth (Apgar score between 4 and 6). 
My analysis makes use of a rich set of individual-level controls available in the U.S. 
Natality Files that may be correlated with both the implementation of MMLs and infant health 
outcome variables. In particular, I use the following variables: sex of infant (1 if male, 0 if 
female), dummies for month of birth (February – December; January is the omitted category), 
dummies for live birth order (1–7; 8+ is the omitted category), age of mother, age of mother 
squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native 
                                                            
7 Available at: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm. 
 
8 For more information on the NCHS data release and access policy, including procedures for requesting data files 
with geographic detail, see: https://www.cdc.gov/nchs/nvss/dvs_data_release.htm. 
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American/Alaskan Native, Asian/Pacific Islander; White is the omitted category), indicator for 
marital status of mother (1 if married, 0 otherwise), dummies for education of mother (8th grade 
or less; some high school; some college; bachelor’s degree; master’s, doctorate, or professional 
degree; high school graduate is the omitted category).9 
I restrict my analysis to singleton births for which at least one health outcome of interest 
(birth weight, gestation, and/or Apgar score) is available. This yields the maximum sample size 
of 94,101,306. The sample breakdowns by year of birth and state are presented in Tables 2.2 and 
2.3, respectively. Descriptive statistics for the full sample are reported in Table 2.4. 
 
2.3.2 State-Level Medical Marijuana Laws 
This chapter makes use of effective dates of state MMLs from the National Conference of State 
Legislatures,10 ProCon.org,11 and the National Organization for the Reform of Marijuana Laws12 
to identify treated and untreated births. I match MMLs to the NCHS natality data based on the 
year when the law went into effect. For the main analysis, I construct an indicator variable for 
whether a state had an MML in effect in the year of birth of a child. For robustness checks, I 
create 3 years of leads and 5 years of lags for the MMLs. 
 
 
 
                                                            
9 I do not use the information on prenatal care, alcohol consumption, and smoking as these behaviors may be 
plausibly endogenous with respect to MMLs, and including them in the analysis may introduce bias in the 
estimation of the effects of MML on birth outcomes. 
 
10 Accessed at: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. 
 
11 Accessed at: http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881. 
 
12 Accessed at: http://norml.org/states. 
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2.3.3 State-Level Control Variables 
In addition to the MMLs, my analysis utilizes controls for time-varying state-level policies and 
characteristics that may be correlated with both the implementation of MMLs and infant health 
outcome variables. In particular, I control for whether a state has decriminalized marijuana (from 
the Marijuana Policy Project13), whether a state has legalized recreational marijuana (from the 
National Organization for the Reform of Marijuana Laws14), unemployment rate (from the 
Bureau of Labor Statistics Local Area Unemployment Statistics Database), cigarette excise taxes 
(from the Tax Foundation15), minimum wages (from the Wage and Hour Division of the United 
States Department of Labor16), state earned income tax credit programs (EITC), whether the state 
EITC is refundable, and the generosity of the state EITC measured as a percentage of federal 
credit (from Tax Credits for Working Families,17 Tax Policy Center of the Urban Institute and 
Brookings Institution,18 and the National Conference of State Legislatures19). 
 
2.4 RESEARCH STRATEGY 
In keeping with the MML literature, I explore the relationship between MMLs and early life 
health measures using a difference-in-differences estimation framework which exploits both 
temporal and geographic variation in the implementation of MMLs. 
                                                            
13 Accessed at: https://www.mpp.org/issues/decriminalization/state-laws-with-alternatives-to-incarceration-for-
marijuana-possession/. 
 
14 Accessed at: http://norml.org/states. 
 
15 Accessed at: https://taxfoundation.org/individual-consumption-taxes/excise-taxes/cigarette-and-tobacco-taxes/. 
 
16 Accessed at: https://www.dol.gov/whd/state/stateMinWageHis.htm. 
 
17 Accessed at: http://www.taxcreditsforworkersandfamilies.org/state-tax-credits/. 
 
18 Accessed at: http://www.taxpolicycenter.org/statistics/state-eitc-based-federal-eitc/. 
 
19 Accessed at: http://www.ncsl.org/research/labor-and-employment/earned-income-tax-credits-for-working-
families.aspx. 
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First, following Anderson et al. (2013), I begin with the baseline equation of the 
following form: !"#$ = 	'( +	'*++,#$ +	-#$'. +	/"#$'0 +	1# +	2$ +	3"#$	,										 (1) 
where !"#$ measures the birth outcome (birth weight, low birth weight status, length of gestation, 
Apgar score, etc.) for a child 5 born in year 6 to a mother residing in state 7, ++,#$ is an 
indicator for whether state 7 had an MML law in effect in year 6, -#$ is a vector of time-varying 
state controls, /"#$ is a vector of individual-level controls, 1# is a state fixed effect (to control for 
permanent differences in outcomes across states), 2$ is a year fixed effect (to control for trends 
in outcomes across years in all states), and 3"#$ is the disturbance. 
 Additionally, following Anderson et al. (2015), Anderson et al. (2014), Sabia and 
Nguyen (2016), and Choi et al. (2016), I experiment with specifications that include state-
specific linear trends (1#×	6) as supplementary right hand-side variables: !"#$ = 	'( +	'*++,#$ +	-#$'. +	/"#$'0 +	1# +	2$ +	1#×	6 +	3"#$	.										 (2) 
These time trends are intended to capture difficult to measure factors such as attitudes that might 
have evolved differently over time in states that legalized medical marijuana compared with 
states that did not. 
Finally, following Chu (2014), Chu (2015), and Sabia et al. (2017), I add state-specific 
quadratic time trends (1#×	6.): !"#$ = 	'( +	'*++,#$ +	-#$'. +	/"#$'0 +	1# +	2$ +	1#×	6 +	1#×	6. 	+	3"#$	.										 (3) 
 I estimate equations (1) – (3) using ordinary least squares and cluster the standard errors 
at the state level to allow for arbitrary correlation among observations in the same state over time 
(Bertrand et al., 2004). 
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The key coefficient of interest in equations (1) – (3) is '* which captures the net effect of 
the MMLs on birth outcomes. It is identified under the assumption that birth outcomes would 
have followed the same trends in states which legalized medical marijuana and states which did 
not, had MMLs not been implemented. Inclusion of state-specific linear and quadratic time 
trends in specifications (2) and (3) relaxes this assumption by allowing for differential trends in 
outcomes of interest. Therefore, these models can account for empirically important unobserved 
cross-state heterogeneity in both levels and trends. Additionally, I test for differential trends in 
birth outcomes by estimating specifications that include leads of MMLs on the right-hand side of 
the estimating equations. 
 
2.5 RESULTS 
2.5.1 Main Analysis of the Effect of Medical Marijuana Laws on Birth Outcomes 
I begin the analysis by investigating whether there were any changes in the state-average birth 
outcomes after MMLs had been passed. Tables 2.5, 2.6, and 2.7 present state-level difference-in-
differences estimates of the effect of MMLs on birth weight, gestation, and Apgar scores, 
respectively. In each of the three tables, each column represents a result from a separate 
regression. Columns (1), (4), (7), and (10) do not include trends, columns (2), (5), (8), and (11) 
contain state-specific linear trends, and columns (3), (6), (9), and (12) add state-specific 
quadratic trends. I find that MMLs did not result in changes in the state-average birth outcomes. 
 Next, I take advantage of the availability of the micro-level data and conduct individual-
level analysis of the effect of MMLs on birth outcomes. Tables 2.8, 2.9, and 2.10 report 
individual-level difference-in-differences estimates of the effect of MMLs on birth weight, 
gestation, and Apgar scores, respectively. In each of the three tables, estimates in Panel A are 
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based on specifications that only use state and year fixed effects, estimates in Panel B are based 
on specifications that add individual-level controls but not state-level controls, and estimates in 
Panel C are based on specifications that include both individual and state-level controls. In every 
panel, each column represents a result from a separate regression. Columns (1), (4), (7), and (10) 
do not include trends, columns (2), (5), (8), and (11) contain state-specific linear trends, and 
columns (3), (6), (9), and (12) add state-specific quadratic trends. 
Table 2.8 does not present any evidence to support the hypothesis that MMLs have a 
negative impact on birth weight. The estimates of '* in regressions with birth weight in grams as 
the dependent variable are statistically significant at conventional levels only in specifications 
without state-specific trends (column (1)) and are, in fact, positive. In specifications that include 
state-specific linear or quadratic trends (columns (2) and (3)), the estimates of '* are statistically 
insignificant at conventional levels and are never negative. Furthermore, in regressions with 
indicators for extremely low birth weight, very low birth weight, and low birth weight as 
outcome variables, the estimates of '* are not statistically significant, and never different from 
zero. 
Similarly, Table 2.9 provides no indication of negative effects of MMLs on gestation. In 
specifications without state-specific trends, the estimates of '* in regressions with gestation in 
weeks as the dependent variable are statistically significant at conventional levels and never 
negative (column (1)), although these results are sensitive to the inclusion of trends. In 
specifications that include state-specific trends, the estimate of '* is only statistically significant 
at the 10% level in Panel C, column 2, and is still positive. Regressions for preterm, late preterm, 
and early term births as outcomes yield estimates of '* that are either statistically significant and 
negative (Panel C, column (4); all Panels, columns (7), (10), and (11)), or statistically 
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insignificant and equal to zero. In specifications that include state-specific quadratic time trends, 
the estimates of '* are not statistically significant at conventional levels. 
Finally, Table 2.10 does not provide strong and consistent evidence of any negative 
effects of MMLs on Apgar scores. Although coefficients on MML indicators are negative and 
statistically significant in Panel C, columns (1) and (2), which would suggest that MMLs 
decrease Apgar scores, these results are not only very small in magnitude (for instance, in Panel 
C, column 2, the estimated effect is a 0.9% decrease in Apgar scores, -0.078/8.903=-0.009) but 
also no longer hold when state-specific quadratic trends are added to the regressions. Similarly, 
columns (4), (5), (7), and (8) in Panel C suggest that MMLs increased the likelihood of severe 
distress and mild distress births, however these results do not withstand the inclusion of state-
specific quadratic trends. 
Taken together, the results from the main analysis do not support the hypothesis that 
MMLs have a negative impact on birth weight or gestation, however the estimated effects of 
MMLs on Apgar scores are specification-dependent and require further investigation. 
 
2.5.2 Lagged Effects of Medical Marijuana Laws on Birth Outcomes 
It is plausible that changes in birth outcomes may take time to occur. In order to investigate 
possible lagged effects of MMLs, I replace the indicator for MMLs in specifications (1), (2), and 
(3) with a contemporaneous MML indicator (takes value 1 in the year of law change only) and 5 
lags of the laws. The estimates of lagged effects of MMLs on birth weight, gestation, and Apgar 
scores are reported in Tables 2.11, 2.12, and 2.13, respectively. In every table, each column 
represents a result from a separate regression. All specifications include state and year fixed 
effects, as well as individual- and state-level controls. Columns (1), (4), (7), and (10) do not 
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include trends, columns (2), (5), (8), and (11) contain state-specific linear trends, and columns 
(3), (6), (9), and (12) add state-specific quadratic trends. 
Table 2.11 provides no evidence of negative lagged effects of MMLs on birth weight 
across the distribution. The estimates of the coefficients on the MML lags are only statistically 
significant in column (1) and are, in fact, positive. 
In Table 2.12, specifications with linear state-specific trends suggest that MMLs decrease 
the likelihood of early term births by 2.4% in the year of law change (-0.006/0.246=-0.024) and 
by 2.8% (-0.007/0.246=-0.028) in the year following the law change without a corresponding 
increase in the likelihood of preterm or late preterm births, as well as increase gestational age by 
0.2% (0.093/38.870=0.002) 5 years after a law goes into effect. These findings, however, no 
longer hold following the inclusion of the state-specific quadratic trends. Specifications with 
state-specific quadratic trends do not identify lagged effects of MMLs and only report a 
contemporaneous 0.4% decrease in the likelihood of early term births in the year of the law 
change (0.001/0.246=0.004). Overall, Table 2.12 does not document any evidence of negative 
effects of MMLs on infant health outcomes. 
In contrast, while results reported in Table 2.13 are sensitive to the inclusion of state-
level linear and quadratic trends, they corroborate the concerns for possible negative effects of 
MMLs on Apgar scores and the associated increased likelihood of severe distress and mild 
distress births raised in the main analysis. All coefficients on the contemporaneous MML 
indicator and the MML lags are always negative for the Apgar score outcome and are always 
positive for the likelihood of severe distress and mild distress births outcomes, although not 
always statistically significant at the conventional levels. For instance, specifications with state-
specific quadratic time trends suggest that MMLs decrease 5-minute Apgar scores by 0.9%  
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(-0.082/8.903=-0.009) one year after the law goes into effect and by 0.8% (-0.071/8.903=-0.008) 
five years after the law goes into effect (these coefficients are statistically significant at the 10% 
level). Severe distress births are estimated to be 25% (0.001/0.004=0.250) more likely one year 
after the law goes into effect. Mild distress births are estimated to be 40% more likely 
(0.004/0.010=0.40) one year after the law goes into effect and 30% more likely 
(0.003/0.010=0.30) two years after the law goes into effect. It is important to note that such large 
in magnitude negative effects of MMLs on the likelihood of severe distress and mild distress 
births should be interpreted with caution. The mean values for these outcomes are 0.004 and 
0.010, respectively, and the low signal-to-noise ratio in these regressions may be in part 
responsible for these results. 
Overall, I find no evidence to suggest any negative, contemporaneous or lagged, effects 
of MMLs on birth weight and gestation, however there is an indication of decreased Apgar 
scores and increased likelihood of severe distress and mild distress births after an MML goes 
into effect. 
 
2.5.3 Robustness Check: Adding Leads and Lags 
The underlying difference-in-differences model used in this chapter relies on the common trends 
assumption which asserts that that the average change in the control group represents the 
counterfactual change in the treatment group in the absence of treatment, or that outcomes in 
treated and untreated groups would have followed common trends had the treatment not 
occurred. If pre-treatment trends in birth outcomes in MML states were different from those in 
non-MML states, this assumption would be violated. 
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In Tables 2.14, 2.15, and 2.16, I present specifications that add 3 years of the policy 
leads, as well as a contemporaneous policy indicator and 5 years of policy lags to the right side 
of the estimating equations to test for pre-treatment trends. Estimates in Tables 2.14, 2.15, and 
2.16 represent results for birth weight, gestation, and Apgar scores, respectively. In every table, 
each column represents a result from a separate regression. All specifications include state and 
year fixed effects, as well as individual- and state-level controls. Columns (1), (4), (7), and (10) 
do not include trends, columns (2), (5), (8), and (11) contain state-specific linear trends, and 
columns (3), (6), (9), and (12) add state-specific quadratic trends. 
Overall, the results of the robustness check of birth weight and gestation estimates are 
mixed and specification-dependent. While analysis of specifications with state-specific linear 
trends in Tables 2.14 and 2.15 supports the common trends assumption for all outcomes except 
early term births, using specifications with state-specific quadratic trends yields different 
findings. Controlling for state-specific quadratic trends, I cannot rule out differential trends for 
birth weight, very low birth weight, low birth weight, gestation, and pre-term births. 
On the other hand, robustness checks of the MML effects on Apgar scores are reassuring 
and provide no evidence that leading up to the effective dates Apgar scores were trending 
differently in MML and non-MML states. 
 
2.5.4 Subsample Analysis: Teenage Mothers, Adult Mothers with Less Than High  
School Diploma, and Black Mothers 
Effects of MMLs on birth outcomes may display significant heterogeneity by age, race, or other 
socio-demographic characteristics. For this analysis, I identify three subsamples of interest based 
on characteristics of women associated with increased likelihood of both poor birth outcomes 
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and/or marijuana use:20 1) teenage mothers (age < 20), 2) mothers with less than high school 
diploma (age 20+), and 3) black mothers. I hypothesize that if MMLs, in fact, negatively 
impacted birth outcomes, the estimation results will be most pronounced and convincing for 
these subsamples. 
Tables 2.17, 2.18, and 2.19 report results of the subsample analysis for birth weight, 
gestation, and Apgar score outcomes, respectively. In each of the three tables, Panel A 
corresponds to the subsample of teenage mothers, Panel B represents adult mothers with less 
than high school diploma, and Panel C displays the estimates for the subsample of black 
mothers. In every table, each column represents a result from a separate regression. All 
specifications include state and year fixed effects, as well as individual- and state-level controls. 
Columns (1), (4), (7), and (10) do not include trends, columns (2), (5), (8), and (11) contain state-
specific linear trends, and columns (3), (6), (9), and (12) add state-specific quadratic trends. 
The findings in Table 2.17 are broadly consistent with the results of the main analysis. 
For birth weight, I do not find substantial differences in results for the subsamples as compared 
to the full sample of births. In Table 2.17, the only estimate of '*which indicates a negative 
relationship between MMLs and infant health is that for mothers with less than high school 
education in the specification with state-specific linear trends (Panel B, column (11)) which 
indicates that MMLs increase the likelihood of low birth weight births by 2.6% 
(0.002/0.077=0.026), however it is only significant at the 10% level and is not robust to the 
exclusion of the trends or the inclusion of state-specific quadratic trends. 
Similarly, Table 2.18 does not present strong evidence of any negative effects of MMLs 
on gestation. Depending on specification, coefficients switch signs, lose or gain significance, and 
                                                            
20 For more information on the characteristics of reproductive-age women associated with marijuana use, see, for 
example, Ko et al. (2015) and Brown et al. (2017), for a meta-analysis of the determinants of poor birth outcomes, 
see, for example, Kramer (1987). 
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are overall not consistent with the hypothesis that MMLs decrease gestation or increase pre-term, 
late-term, or early term births. 
On the other hand, in Table 2.19, estimates of '* are always negative for specifications 
with Apgar score on the left-hand side of the estimating equation and are always positive for 
specifications with severe distress and mild distress birth indicators as outcomes (although not 
always statistically significant and never significant at the 1% level). This is generally consistent 
with the hypothesis that MMLs decrease Apgar scores. Furthermore, while the magnitude of the 
effect of MMLs on Apgar scores is very small even when the estimates of '* are statistically 
significant (1.1%–1.3% depending on the subsample in specifications with state-specific linear 
trends), the effects on the likelihood of severe distress and mild distress births are economically 
large. For instance, controlling for state-level quadratic trends, I find that the enactment of 
MMLs is associated with substantial increases in the likelihood of severe distress (22%, 
0.002/0.009=0.22) and mild distress births (40%, 0.006/0.015=0.40) for black mothers. 
 
2.6 DISCUSSION AND CONCLUSION 
This chapter provides an investigation focused on examining the impact of the state-level MMLs 
on birth outcomes. Combining data on the entire universe of births in the U.S. between 1990 and 
2013 with the effective dates of the state-level MMLs in a difference-in-differences estimation 
framework, and making use of a rich set of individual-level and state-level characteristics, as 
well as state-specific time trends, I do not find evidence to support the hypothesis that MMLs 
have a negative impact on birth weight or gestation, however I find that MMLs are associated 
with decreases in Apgar scores and increased likelihood of severe distress and mild distress 
births. 
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 This analysis is not without limitations. This study uses a reduced form approach rather 
than a structural model. The effects of MMLs on birth outcomes obtained in this chapter should 
be interpreted as intent-to-treat (ITT) estimates rather than the average treatment effect on the 
treated (ATET). While there is a significant degree of heterogeneity in MMLs across states,21 I 
do not explore it and instead estimate the impact of an “average” MML. Any spillover effects of 
marijuana liberalization on neighboring states are not captured in this analysis. This chapter does 
not consider potential longer-run child health outcomes which may plausibly be impacted by 
MMLs. 
Analysis of both direct and indirect effects of MMLs must be considered in policy 
decisions regarding regulation of marijuana. This study provides new information to the current 
policy debate surrounding marijuana liberalization legislation. 
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Figure 2.1: State-Level Medical Marijuana Laws Implemented Between 1990 – 2013 
 
Notes: Shaded areas represent states which legalized medical marijuana between years 1990 and 2013. 
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Table 2.1: Medical Marijuana Laws, 1990–2013 
 
State Date of Passage of Original Legislation Effective Date 
   
Alaska November 3, 1998 March 4, 1999 
Arizona November 2, 2010 April 14, 2011 
California November 5, 1996 November 6, 1996 
Colorado November 7, 2000 June 1, 2001 
Connecticut May 31, 2012 October 1, 2012 
Delaware May 13, 2011 July 1, 2011 
District of Columbia May 4, 2010 July 27, 2010 
Hawaii June 14, 2000 December 28, 2000 
Maine November 2, 1999 December 22, 1999 
Massachusetts November 6, 2012 January 1, 2013 
Michigan November 4, 2008 December 4, 2008 
Montana November 2, 2004 November 2, 2004 
Nevada November 7, 2000 October 1, 2001 
New Hampshire July 23, 2013 July 23, 2013 
New Jersey January 18, 2010 October 1, 2010 
New Mexico April 2, 2007 July 1, 2007 
Oregon November 3, 1998 December 3, 1998 
Rhode Island January 3, 2006 January 3, 2006 
Vermont May 26, 2004 July 1, 2004 
Washington November 3, 1998 November 3, 1998 
   
Total: 19 states and DC   
 
Notes: These dates for state-level medical marijuana laws are gathered from the National Conference of State 
Legislatures (accessed at: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx), ProCon.org 
(accessed at: http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881), and the National 
Organization for the Reform of Marijuana Laws (accessed at: http://norml.org/states). Arkansas, Florida, Illinois, 
Maryland, Minnesota, New York, North Dakota, Ohio, Pennsylvania, and West Virginia legalized medical 
marijuana after 2013. 
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Table 2.2: Sample Breakdown by Year of Birth 
 
Year of Birth N 
  
1990 4,060,387 
1991 4,011,937 
1992 3,964,954 
1993 3,898,885 
1994 3,850,201 
1995 3,797,223 
1996 3,783,467 
1997 3,769,037 
1998 3,822,070 
1999 3,836,407 
2000 3,930,760 
2001 3,896,575 
2002 3,888,605 
2003 3,953,194 
2004 3,972,124 
2005 3,998,184 
2006 4,121,010 
2007 4,170,461 
2008 4,101,975 
2009 3,986,391 
2010 3,860,921 
2011 3,815,444 
2012 3,816,428 
2013 3,794,666 
Total: 94,101,306 
 
Notes: Underlying data from NCHS. Observations (N) represent maximum sample size. 
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Table 2.3: Sample Breakdown by State 
 
State N 
Alabama   1,424,544 
Alaska      251,419 
Arizona   1,957,502 
Arkansas      876,343 
California 12,712,826 
Colorado   1,461,307 
Connecticut      983,134 
Delaware      256,584 
District of Columbia     207,604 
Florida   4,842,663 
Georgia   2,984,276 
Hawaii      434,351 
Idaho      484,729 
Illinois   4,173,027 
Indiana   1,988,593 
Iowa     893,179 
Kansas     913,088 
Kentucky   1,285,031 
Louisiana   1,534,795 
Maine      327,480 
Maryland   1,727,037 
Massachusetts   1,835,435 
Michigan   3,025,968 
Minnesota   1,579,375 
Mississippi      985,232 
Missouri   1,784,262 
Montana      269,710 
Nebraska      580,514 
Nevada      727,426 
New Hampshire      333,522 
New Jersey   2,628,339 
New Mexico      653,781 
New York   6,007,346 
North Carolina   2,681,296 
North Dakota      200,998 
Ohio   3,508,676 
Oklahoma   1,174,459 
Oregon   1,049,616 
Pennsylvania   3,477,182 
Rhode Island      293,305 
South Carolina   1,314,463 
South Dakota      260,009 
Tennessee   1,824,710 
Texas   8,428,949 
Utah   1,090,529 
Vermont      155,911 
Virginia   2,320,104 
Washington   1,917,903 
West Virginia      494,019 
Wisconsin   1,617,210 
Wyoming      161,545 
Total: 94,101,306 
 
Notes: Underlying data from NCHS. Observations (N) represent maximum sample size. 
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Table 2.4: Descriptive Statistics 
 
 Full Sample MML States Never-MML States P-values 
 N Mean S. D. N Mean S. D. N Mean S. D.  
Outcome variables           
Birth weight (g) 94,028,349 3,329.472 572.744 31,461,140 3,354.837 561.881 62,567,209 3,316.718 577.709 0.000 
Extremely low birth weight (<1,000 g) 94,028,349 0.006 0.074 31,461,140 0.005 0.068 62,567,209 0.006 0.077 0.000 
Very low birth weight (<1,500 g) 94,028,349 0.011 0.104 31,461,140 0.009 0.097 62,567,209 0.012 0.108 0.000 
Low birth weight (<2,500 g) 94,028,349 0.062 0.241 31,461,140 0.055 0.228 62,567,209 0.065 0.247 0.000 
Normal birth weight (2,500 to 3,999 g) 94,028,349 0.844 0.363 31,461,140 0.845 0.362 62,567,209 0.844 0.363 0.000 
Gestation (weeks) 93,438,700 38.869 2.477 30,966,097 38.973 2.374 62,472,603 38.817 2.525 0.000 
Preterm (< 37 weeks) 93,438,700 0.102 0.303 30,966,097 0.092 0.289 62,472,603 0.107 0.310 0.000 
Late preterm (34 – 36 weeks) 93,438,700 0.074 0.262 30,966,097 0.068 0.251 62,472,603 0.077 0.266 0.000 
Early term (37 – 38 weeks) 93,438,700 0.246 0.431 30,966,097 0.235 0.424 62,472,603 0.252 0.434 0.000 
5-minute Apgar score 79,458,604 8.893 0.765 22,174,445 8.881 0.718 57,284,159 8.898 0.782 0.000 
Severe distress (Apgar 0 – 3) 79,458,604 0.004 0.067 22,174,445 0.004 0.062 57,284,159 0.005 0.068 0.000 
Mild distress (Apgar 4 – 6) 79,458,604 0.010 0.100 22,174,445 0.009 0.009 57,284,159 0.010 0.102 0.000 
Individual-level control variables 
Male 94,101,306 0.512 0.500 31,483,123 0.512 0.500 62,618,183 0.512 0.500 0.000 
Live birth order 93,624,352 2.044 1.214 31,325,353 2.058 1.228 62,298,999 2.036 1.207 0.000 
Age of mother 94,101,306 27.150 6.093 31,483,123 27.690 6.161 62,618,183 26.879 6.040 0.000 
Hispanic 93,154,836 0.210 0.407 31,021,635 0.311 0.463 62,133,201 0.159 0.366 0.000 
White 94,095,713 0.782 0.413 31,483,123 0.807 0.395 62,618,183 0.769 0.421 0.000 
Black 94,095,713 0.156 0.363 31,483,123 0.090 0.287 62,618,183 0.190 0.392 0.000 
Native American/Alaskan Native 94,095,713 0.011 0.103 31,483,123 0.017 0.129 62,618,183 0.008 0.087 0.000 
Asian/Pacific Islander 94,095,713 0.051 0.220 31,483,123 0.086 0.280 62,618,183 0.033 0.180 0.000 
Married 94,101,306 0.646 0.478 31,483,123 0.656 0.475 62,618,183 0.640 0.480 0.000 
Education: 8th grade or less 89,076,524 0.059 0.235 29,214,682 0.076 0.265 59,861,842 0.050 0.218 0.000 
Education: Some HS 89,076,524 0.158 0.365 29,214,682 0.157 0.364 59,861,842 0.159 0.366 0.000 
Education: HS grad 89,076,524 0.312 0.463 29,214,682 0.298 0.457 59,861,842 0.319 0.466 0.000 
Education: Some college 89,076,524 0.232 0.422 29,214,682 0.226 0.418 59,861,842 0.235 0.424 0.000 
Education: Bachelor’s degree 89,076,524 0.152 0.359 29,214,682 0.151 0.358 59,861,842 0.152 0.359 0.000 
Education: Masters, doctorate, or 
professional degree 
89,076,524 0.087 0.282 29,214,682 0.093 0.290 59,861,842 0.084 0.359 0.000 
State-level control variables 
Marijuana decriminalized 94,101,306 0.341 0.474 31,483,123 0.531 0.499 62,618,183 0.245 0.430 0.000 
Recreational marijuana legalized 94,101,306 0.003 0.056 31,483,123 0.009 0.962 62,618,183 0.000 0.000 0.000 
Unemployment rate (%) 94,101,306 6.157 1.943 31,483,123 6.726 2.167 62,618,183 5.871 1.752 0.000 
Cigarette excise tax (cents/pack) 94,101,306 70.578 67.895 31,483,123 90.030 67.978 62,618,183 60.801 65.714 0.000 
Minimum wage 94,101,306 5.559 1.284 31,483,123 5.895 1.445 62,618,183 5.390 1.159 0.000 
State EITC 94,101,306 0.253 0.435 31,483,123 0.208 0.406 62,618,183 0.275 0.447 0.000 
State refundable EITC 94,101,306 0.233 0.423 31,483,123 0.205 0.404 62,618,183 0.247 0.431 0.000 
% of Federal EITC 94,101,306 4.791 9.488 31,483,123 3.721 8.589 62,618,183 5.330 9.866 0.000 
Treatment variable  
MML 94,101,306 0.161 0.368 31,483,123 0.483 0.500 62,618,183 0.000 0.000 0.000 
Notes: Underlying data from NCHS. Sample means and standard deviations are reported. Observations (N) represent maximum sample size.  
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Table 2.5: State-Level Difference-in-Differences Estimates of the Effect of Medical Marijuana Laws on Birth Weight Across 
the Distribution 
 
 Birth weight (g) Extremely low birth weight 
(<1,000 g) 
Very low birth weight 
(<1,500 g) 
Low birth weight 
(<2,500 g) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
MML 10.803** 
(3.595) 
-0.077 
(3.364) 
2.262 
(1.746) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.000) 
Outcome mean (MML = 0) 3,331.473 0.006 0.011 0.063 
N 1,224 1,224 1,224 1,224 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
 
Notes: Each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. State-level controls 
included but not shown: share of male births, average live birth order, average age of mother, average age of mother squared, share of mothers of Hispanic origin, share of Black mothers, 
share of Native American/Alaskan Native mothers, share of Asian/Pacific Islander mothers, share of married mothers, share of mothers with educational attainment of 8th grade or less, share 
of mothers with some high school education, share of mothers with some college education, share of mothers with a bachelor’s degree, share of mothers with a master’s, doctorate, or 
professional degree, marijuana decriminalization status, recreational marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the 
state EITC is refundable, generosity of the state EITC measured as a percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10. 
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Table 2.6: State-Level Difference-in-Differences Estimates of the Effect of Medical Marijuana Laws on Gestation Across the 
Distribution 
 
 Gestation (weeks) Preterm 
(<37 weeks) 
Late preterm 
(34 – 36 weeks) 
Early term 
(37 – 38 weeks) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
MML 0.062*** 
(0.023) 
-0.004 
(0.017) 
-0.010 
(0.010) 
-0.001 
(0.001) 
0.001 
(0.001) 
-0.001 
(0.001) 
-0.002* 
(0.001) 
-0.000 
(0.001) 
-0.001* 
(0.001) 
-0.014*** 
(0.004) 
-0.001 
(0.003) 
-0.001 
(0.003) 
Outcome mean (MML = 0) 38.884 0.103 0.074 0.244 
N 1,224 1,224 1,224 1,224 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
 
Notes: Each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. State-level controls 
included but not shown: share of male births, average live birth order, average age of mother, average age of mother squared, share of mothers of Hispanic origin, share of Black mothers, 
share of Native American/Alaskan Native mothers, share of Asian/Pacific Islander mothers, share of married mothers, share of mothers with educational attainment of 8th grade or less, share 
of mothers with some high school education, share of mothers with some college education, share of mothers with a bachelor’s degree, share of mothers with a master’s, doctorate, or 
professional degree, marijuana decriminalization status, recreational marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the 
state EITC is refundable, generosity of the state EITC measured as a percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.7: State-Level Difference-in-Differences Estimates of the Effect of Medical Marijuana Laws on Apgar Scores Across 
the Distribution 
 
 5-Minute Apgar Score Severe Distress 
(Apgar Score 0 – 3) 
Mild Distress 
(Apgar Score 4 – 6) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
MML -0.009 
(0.028) 
-0.004 
(0.031) 
-0.026 
(0.022) 
0.000 
(0.000) 
0.001 
(0.001) 
0.000 
(0.000) 
0.002 
(0.001) 
0.002 
(0.001) 
0.001 
(0.001) 
Outcome mean (MML = 0) 8.887 0.005 0.011 
N 1,224 1,224 1,224 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes 
 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.8: Individual-Level Difference-in-Differences Estimates of the Effect of Medical Marijuana Laws on Birth Weight 
Across the Distribution 
 
 Birth weight (g) Extremely low birth weight 
(<1,000 g) 
Very low birth weight 
(<1,500 g) 
Low birth weight 
(<2,500 g) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
Panel A: Difference-in-differences, no individual- or state-level controls 
MML 6.142** 
(2.963) 
2.277 
(4.679) 
1.103 
(1.608) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.001) 
0.000 
(0.001) 
0.000 
(0.000) 
Outcome mean (MML = 0) 3,326.050 0.006 0.011 0.063 
N 94,028,349 94,028,349 94,028,349 94,028,349 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls No No No No No No No No No No No No 
State-level controls No No No No No No No No No No No No 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Panel B: Difference-in-differences, individual-level controls, no state-level controls 
MML 6.190** 
(2.909) 
4.517 
(4.172) 
0.860 
(1.843) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.001) 
-0.000 
(0.001) 
-0.000 
(0.000) 
Outcome mean (MML = 0) 3,328.076 0.006 0.011 0.063 
N 87,911,694 87,911,694 87,911,694 87,911,694 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls No No No No No No No No No No No No 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Panel C: Difference-in-differences, individual- and state-level controls 
MML 4.750** 
(2.394) 
3.721 
(3.825) 
0.440 
(1.999) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.001) 
-0.000 
(0.001) 
0.000 
(0.000) 
Outcome mean (MML = 0) 3,328.076 0.006 0.011 0.063 
N 87,911,694 87,911,694 87,911,694 87,911,694 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. Individual-level 
controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is the omitted category), age 
of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific Islander; White is the omitted category), 
indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; master’s, doctorate, or professional degree; high school 
graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational marijuana legalization status, unemployment rate, state earned income tax 
credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.9: Individual-Level Difference-in-Differences Estimates of the Effect of Medical Marijuana Laws on Gestation Across 
the Distribution 
 
 Gestation (weeks) Preterm 
(<37 weeks) 
Late preterm 
(34 – 36 weeks) 
Early term 
(37 – 38 weeks) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
Panel A: Difference-in-differences, no individual- or state-level controls 
MML 0.048** 
(0.019) 
0.020 
(0.022) 
-0.003 
(0.007) 
-0.003 
(0.002) 
0.001 
(0.001) 
0.001 
(0.001) 
-0.003* 
(0.002) 
0.000 
(0.001) 
0.000 
(0.000) 
-0.012*** 
(0.003) 
-0.006* 
(0.003) 
-0.001 
(0.002) 
Outcome mean (MML = 0) 38.862 0.105 0.075 0.246 
N 93,438,700 93,438,700 93,438,700 93,438,700 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls No No No No No No No No No No No No 
State-level controls No No No No No No No No No No No No 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Panel B: Difference-in-differences, individual-level controls, no state-level controls 
MML 0.050** 
(0.019) 
0.027 
(0.022) 
-0.005 
(0.005) 
-0.003 
(0.002) 
0.001 
(0.001) 
0.001 
(0.001) 
-0.003* 
(0.002) 
-0.000 
(0.001) 
0.000 
(0.000) 
-0.013*** 
(0.003) 
-0.007* 
(0.004) 
-0.000 
(0.001) 
Outcome mean (MML = 0) 38.870 0.104 0.075 0.246 
N 87,405,874 87,405,874 87,405,874 87,405,874 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls No No No No No No No No No No No No 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Panel C: Difference-in-differences, individual- and state-level controls 
MML 0.049*** 
(0.014) 
0.026* 
(0.015) 
-0.007 
(0.005) 
-0.003** 
(0.002) 
0.001 
(0.001) 
0.001 
(0.001) 
-0.004*** 
(0.001) 
-0.000 
(0.000) 
0.000 
(0.000) 
-0.009*** 
(0.002) 
-0.006** 
(0.003) 
-0.000 
(0.001) 
Outcome mean (MML = 0) 38.870 0.104 0.075 0.246 
N 87,405,874 87,405,874 87,405,874 87,405,874 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. Individual-level 
controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is the omitted category), age 
of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific Islander; White is the omitted category), 
indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; master’s, doctorate, or professional degree; high school 
graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational marijuana legalization status, unemployment rate, state earned income tax 
credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.10: Individual-Level Difference-in-Differences Estimates of the Effect of Medical Marijuana Laws on Apgar Scores 
Across the Distribution 
 
 5-Minute Apgar Score Severe Distress 
(Apgar Score 0 – 3) 
Mild Distress 
(Apgar Score 4 – 6) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
Panel A: Difference-in-differences, no individual- or state-level controls 
MML -0.024 
(0.033) 
-0.047 
(0.041) 
-0.052 
(0.033) 
0.001 
(0.001) 
0.001 
(0.001) 
0.001 
(0.001) 
0.002* 
(0.001) 
0.002 
(0.002) 
0.003* 
(0.002) 
Outcome mean (MML = 0) 8.902 0.004 0.010 
N 79,458,604 79,458,604 79,458,604 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls No No No No No No No No No 
State-level controls No No No No No No No No No 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes 
Panel B: Difference-in-differences, individual-level controls, no state-level controls 
MML -0.050 
(0.034) 
-0.079* 
(0.045) 
-0.061 
(0.042) 
0.001** 
(0.001) 
0.001* 
(0.001) 
0.001 
(0.001) 
0.004*** 
(0.001) 
0.004** 
(0.002) 
0.003 
(0.002) 
Outcome mean (MML = 0) 8.903 0.004 0.010 
N 73,725,046 73,725,046 73,725,046 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls No No No No No No No No No 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes 
Panel C: Difference-in-differences, individual- and state-level controls 
MML -0.062** 
(0.030) 
-0.078* 
(0.037) 
-0.059 
(0.043) 
0.001*** 
(0.000) 
0.001* 
(0.001) 
0.001 
(0.001) 
0.004*** 
(0.001) 
0.004** 
(0.002) 
0.003 
(0.002) 
Outcome mean (MML = 0) 8.903 0.004 0.010 
N 73,725,046 73,725,046 73,725,046 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. Individual-level 
controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is the omitted category), age 
of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific Islander; White is the omitted category), 
indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; master’s, doctorate, or professional degree; high school 
graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational marijuana legalization status, unemployment rate, state earned income tax 
credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.11: Lagged Effects of Medical Marijuana Laws on Birth Weight Across the Distribution 
 
 Birth weight (g) Extremely low birth weight 
(<1,000 g) 
Very low birth weight 
(<1,500 g) 
Low birth weight 
(<2,500 g) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
Year of law change 2.435 
(1.980) 
0.703 
(2.967) 
-1.519 
(1.948) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.001) 
0.000 
(0.001) 
0.000 
(0.000) 
1 year after MML 5.928*** 
(1.999) 
3.890 
(3.177) 
1.670 
(1.884) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.001 
(0.001) 
-0.000 
(0.001) 
-0.000 
(0.001) 
2 years after MML 7.607*** 
(2.213) 
4.890 
(4.536) 
2.930 
(2.895) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.001 
(0.001) 
-0.000 
(0.001) 
-0.000 
(0.001) 
3 years after MML 8.417*** 
(2.374) 
6.881 
(6.225) 
5.696 
(3.725) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.001 
(0.001) 
-0.000 
(0.001) 
-0.001 
(0.001) 
4 years after MML 6.485** 
(2.511) 
5.451 
(6.537) 
4.233 
(3.436) 
0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.001) 
0.000 
(0.001) 
-0.000 
(0.001) 
5+ years after MML 3.322 
(3.499) 
4.482 
(7.241) 
4.992 
(3.794) 
0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.001) 
-0.000 
(0.001) 
-0.001 
(0.001) 
Outcome mean (MML = 0) 3,328.076 0.006 0.011 0.063 
N 87,911,694 87,911,694 87,911,694 87,911,694 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.12: Lagged Effects of Medical Marijuana Laws on Gestation Across the Distribution 
 
 Gestation (weeks) Preterm 
(<37 weeks) 
Late preterm 
(34 – 36 weeks) 
Early term 
(37 – 38 weeks) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
Year of law change 0.028** 
(0.011) 
0.018 
(0.013) 
-0.005 
(0.006) 
0.000 
(0.001) 
0.001 
(0.001) 
0.001 
(0.001) 
0.001 
(0.001) 
0.000 
(0.001) 
0.000 
(0.000) 
-0.009*** 
(0.002) 
-0.006*** 
(0.002) 
-0.001* 
(0.001) 
1 year after MML 0.040*** 
(0.013) 
0.033 
(0.020) 
0.010 
(0.011) 
-0.002 
(0.001) 
0.000 
(0.001) 
-0.000 
(0.001) 
-0.002** 
(0.001) 
-0.000 
(0.000) 
-0.000 
(0.001) 
-0.009*** 
(0.002) 
-0.007** 
(0.003) 
-0.001 
(0.001) 
2 years after MML 0.037** 
(0.014) 
0.030 
(0.022) 
0.004 
(0.012) 
0.001 
(0.001) 
0.001 
(0.001) 
0.000 
(0.001) 
-0.002* 
(0.001) 
0.000 
(0.001) 
-0.000 
(0.001) 
-0.010*** 
(0.003) 
-0.007 
(0.004) 
-0.001 
(0.002) 
3 years after MML 0.037** 
(0.014) 
0.040 
(0.028) 
0.012 
(0.014) 
-0.002 
(0.002) 
0.002 
(0.001) 
0.000 
(0.001) 
-0.002* 
(0.001) 
0.000 
(0.001) 
0.000 
(0.001) 
-0.008*** 
(0.003) 
-0.007 
(0.006) 
-0.000 
(0.003) 
4 years after MML 0.048*** 
(0.015) 
0.056 
(0.034) 
0.030 
(0.017) 
-0.003* 
(0.002) 
0.001 
(0.001) 
-0.001 
(0.001) 
-0.004*** 
(0.001) 
-0.001 
(0.001) 
-0.001 
(0.001) 
-0.009*** 
(0.003) 
-0.009 
(0.007) 
-0.002 
(0.004) 
5+ years after MML 0.063*** 
(0.019) 
0.093** 
(0.045) 
0.050 
(0.030) 
-0.006** 
(0.003) 
0.000 
(0.001) 
-0.001 
(0.002) 
-0.006*** 
(0.002) 
-0.001 
(0.001) 
-0.001 
(0.001) 
-0.010*** 
(0.003) 
-0.012 
(0.009) 
-0.004 
(0.005) 
Outcome mean (MML = 0) 38.870 0.104 0.075 0.246 
N 87,405,874 87,405,874 87,405,874 87,405,874 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.13: Lagged Effects of Medical Marijuana Laws on Apgar Scores Across the Distribution 
 
 5-Minute Apgar Score Severe Distress 
(Apgar Score 0 – 3) 
Mild Distress 
(Apgar Score 4 – 6) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
Year of law change -0.052 
(0.465) 
-0.066 
(0.044) 
-0.059 
(0.046) 
0.001 
(0.001) 
0.001 
(0.001) 
0.001 
(0.001) 
0.003* 
(0.002) 
0.003 
(0.002) 
0.003 
(0.002) 
1 year after MML -0.084* 
(0.046) 
-0.103** 
(0.042) 
-0.082* 
(0.043) 
0.001** 
(0.001) 
0.002** 
(0.001) 
0.001** 
(0.001) 
0.005** 
(0.002) 
0.005** 
(0.002) 
0.004** 
(0.002) 
2 years after MML -0.062 
(0.041) 
-0.084** 
(0.037) 
-0.058 
(0.039) 
0.001* 
(0.001) 
0.001** 
(0.001) 
0.001 
(0.001) 
0.004** 
(0.002) 
0.004** 
(0.002) 
0.003* 
(0.002) 
3 years after MML -0.049 
(0.038) 
-0.073** 
(0.032) 
-0.035 
(0.036) 
0.001* 
(0.001) 
0.001** 
(0.001) 
0.000 
(0.001) 
0.003** 
(0.002) 
0.003* 
(0.001) 
0.001 
(0.002) 
4 years after MML -0.056 
(0.038) 
-0.086*** 
(0.030) 
-0.033 
(0.036) 
0.001** 
(0.001) 
0.001** 
(0.000) 
0.000 
(0.000) 
0.004** 
(0.001) 
0.004*** 
(0.001) 
0.001 
(0.002) 
5+ years after MML -0.064** 
(0.028) 
-0.148*** 
(0.039) 
-0.071* 
(0.041) 
0.002*** 
(0.001) 
0.002*** 
(0.001) 
0.001 
(0.001) 
0.005*** 
(0.001) 
0.006*** 
(0.002) 
0.003 
(0.002) 
Outcome mean (MML = 0) 8.903 0.004 0.010 
N 73,725,046 73,725,046 73,725,046 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes 
 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10. 
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Table 2.14: Robustness Check: Effect of Medical Marijuana Laws on Birth Weight Across the Distribution,  
Adding Leads and Lags 
 
 Birth weight (g) Extremely low birth weight 
(<1,000 g) 
Very low birth weight 
(<1,500 g) 
Low birth weight 
(<2,500 g) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
3 years before MML -0.041 
(2.771) 
-0.910 
(1.700) 
-3.750*** 
(1.361) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.001 
(0.001) 
0.000 
(0.000) 
0.001* 
(0.000) 
2 years before MML 0.198 
(3.263) 
-0.407 
(1.924) 
-5.601** 
(2.266) 
0.000 
(0.000) 
0.000** 
(0.000) 
0.000*** 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.001*** 
(0.000) 
0.001 
(0.001) 
0.000 
(0.000) 
0.001* 
(0.001) 
1 year before MML 2.454 
(2.842) 
0.815 
(3.217) 
-6.556** 
(2.742) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000* 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.001** 
(0.000) 
0.000 
(0.001) 
0.000 
(0.001) 
0.002** 
(0.001) 
Year of law change 2.843 
(2.880) 
0.660 
(4.090) 
-7.768** 
(3.241) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.001** 
(0.000) 
0.000 
(0.001) 
0.000 
(0.001) 
0.002** 
(0.001) 
1 year after MML 6.377** 
(3.111) 
3.865 
(4.458) 
-5.420 
(3.491) 
-0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000* 
(0.000) 
-0.000 
(0.001) 
0.000 
(0.001) 
0.001 
(0.001) 
2 years after MML 8.024*** 
(3.015) 
4.856 
(5.721) 
-4.906 
(4.027) 
-0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.001 
(0.001) 
0.000 
(0.001) 
0.002* 
(0.001) 
3 years after MML 8.827*** 
(3.192) 
6.850 
(7.386) 
-2.830 
(4.736) 
-0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.001 
(0.001) 
-0.000 
(0.001) 
0.001 
(0.001) 
4 years after MML 6.931** 
(3.249) 
5.436 
(7.728) 
-4.925 
(4.816) 
0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.001 
(0.000) 
0.000 
(0.001) 
0.001 
(0.001) 
0.002* 
(0.001) 
5+ years after MML 3.731 
(4.331) 
4.472 
(8.608) 
-5.448 
(5.397) 
0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.001) 
-0.000 
(0.001) 
0.002 
(0.001) 
Outcome mean (MML = 0) 3,328.076 0.006 0.011 0.063 
N 87,911,694 87,911,694 87,911,694 87,911,694 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.15: Robustness Check: Effect of Medical Marijuana Laws on Gestation Across the Distribution, 
Adding Leads and Lags 
 
 Gestation (weeks) Preterm 
(<37 weeks) 
Late preterm 
(34 – 36 weeks) 
Early term 
(37 – 38 weeks) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
3 years prior to MML 0.005 
(0.012) 
0.008 
(0.014) 
0.007 
(0.007) 
0.001 
(0.001) 
0.000 
(0.001) 
0.001 
(0.001) 
0.000 
(0.001) 
-0.000 
(0.001) 
0.000 
(0.001) 
-0.003 
(0.002) 
-0.002 
(0.003) 
0.001 
(0.002) 
2 years prior to MML 0.022 
(0.015) 
0.015 
(0.013) 
-0.017* 
(0.009) 
0.000 
(0.001) 
0.001 
(0.001) 
0.002* 
(0.001) 
-0.001 
(0.001) 
-0.000 
(0.001) 
0.000 
(0.001) 
-0.007** 
(0.003) 
-0.005** 
(0.002) 
0.001 
(0.002) 
1 year prior to MML 0.025 
(0.016) 
0.020 
(0.015) 
-0.026** 
(0.012) 
0.001 
(0.001) 
0.001 
(0.001) 
0.003*** 
(0.001) 
-0.000 
(0.001) 
0.000 
(0.001) 
0.001 
(0.001) 
-0.009*** 
(0.003) 
-0.007** 
(0.003) 
0.001 
(0.002) 
Year of law change 0.036** 
(0.016) 
0.028 
(0.020) 
-0.026* 
(0.013) 
0.000 
(0.001) 
0.002* 
(0.001) 
0.003** 
(0.001) 
-0.001 
(0.001) 
0.000 
(0.001) 
0.001 
(0.001) 
-0.012*** 
(0.003) 
-0.010*** 
(0.003) 
-0.001 
(0.002) 
1 year after MML 0.049*** 
(0.017) 
0.044 
(0.027) 
-0.014 
(0.016) 
-0.001 
(0.001) 
0.001 
(0.001) 
0.002 
(0.001) 
-0.002** 
(0.001) 
-0.001 
(0.001) 
0.000 
(0.001) 
-0.012*** 
(0.003) 
-0.011** 
(0.004) 
-0.000 
(0.003) 
2 years after MML 0.046** 
(0.019) 
0.041 
(0.029) 
-0.022 
(0.019) 
-0.001 
(0.002) 
0.002* 
(0.001) 
0.003** 
(0.001) 
-0.002* 
(0.001) 
-0.000 
(0.001) 
0.000 
(0.001) 
-0.013*** 
(0.003) 
-0.011* 
(0.005) 
0.000 
(0.004) 
3 years after MML 0.045** 
(0.019) 
0.052 
(0.036) 
-0.017 
(0.022) 
-0.002 
(0.002) 
0.002* 
(0.001) 
0.003* 
(0.002) 
-0.002 
(0.001) 
0.000 
(0.001) 
0.001 
(0.001) 
-0.010*** 
(0.003) 
-0.011 
(0.007) 
0.001 
(0.004) 
4 years after MML 0.057*** 
(0.189) 
0.069 
(0.042) 
-0.008 
(0.023) 
-0.003 
(0.002) 
0.001 
(0.002) 
0.002 
(0.002) 
-0.004* 
(0.002) 
-0.001 
(0.001) 
-0.000 
(0.001) 
-0.012*** 
(0.003) 
-0.013 
(0.008) 
-0.001 
(0.004) 
5+ years after MML 0.071*** 
(0.023) 
0.108** 
(0.054) 
0.014 
(0.035) 
-0.006** 
(0.003) 
0.001 
(0.002) 
0.002 
(0.002) 
-0.006*** 
(0.002) 
-0.001 
(0.001) 
-0.000 
(0.001) 
-0.012*** 
(0.004) 
-0.017* 
(0.010) 
-0.003 
(0.005) 
Outcome mean (MML = 0) 38.870 0.104 0.075 0.246 
N 87,405,874 87,405,874 87,405,874 87,405,874 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.16: Robustness Check: Effect of Medical Marijuana Laws on Apgar Scores Across the Distribution,  
Adding Leads and Lags 
 
 5-Minute Apgar Score Severe Distress 
(Apgar Score 0 – 3) 
Mild Distress 
(Apgar Score 4 – 6) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
3 years before MML 0.024* 
(0.012) 
0.010 
(0.009) 
0.010 
(0.008) 
-0.000* 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.001) 
-0.001 
(0.000) 
-0.000 
(0.000) 
2 years before MML 0.025* 
(0.013) 
0.012 
(0.013) 
0.011 
(0.011) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.001) 
-0.000 
(0.001) 
-0.000 
(0.001) 
1 year before MML 0.006 
(0.014) 
-0.011 
(0.015) 
-0.006 
(0.018) 
0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
0.001 
(0.001) 
0.001 
(0.001) 
0.000 
(0.001) 
Year of law change -0.045 
(0.046) 
-0.065 
(0.045) 
-0.055 
(0.049) 
0.001 
(0.000) 
0.001 
(0.001) 
0.001 
(0.001) 
0.004* 
(0.002) 
0.003 
(0.002) 
0.003 
(0.002) 
1 year after MML -0.077 
(0.047) 
-0.101** 
(0.044) 
-0.078* 
(0.043) 
0.001** 
(0.001) 
0.002** 
(0.001) 
0.001* 
(0.001) 
0.005** 
(0.002) 
0.005** 
(0.002) 
0.004* 
(0.002) 
2 years after MML -0.055 
(0.042) 
-0.083** 
(0.039) 
-0.053 
(0.040) 
0.001* 
(0.001) 
0.001* 
(0.001) 
0.001 
(0.001) 
0.004** 
(0.002) 
0.004** 
(0.002) 
0.003 
(0.002) 
3 years after MML -0.043 
(0.039) 
-0.071** 
(0.036) 
-0.030 
(0.041) 
0.001* 
(0.001) 
0.001* 
(0.001) 
0.000 
(0.001) 
0.003* 
(0.002) 
0.003* 
(0.002) 
0.001 
(0.002) 
4 years after MML -0.049 
(0.040) 
-0.084** 
(0.035) 
-0.027 
(0.043) 
0.001** 
(0.001) 
0.001* 
(0.001) 
0.000 
(0.001) 
0.004** 
(0.002) 
0.003** 
(0.002) 
0.001 
(0.002) 
5+ years after MML -0.056 
(0.029) 
-0.145*** 
(0.043) 
-0.065 
(0.050) 
0.002*** 
(0.001) 
0.002** 
(0.001) 
0.001 
(0.001) 
0.005*** 
(0.001) 
0.006*** 
(0.002) 
0.003 
(0.003) 
Outcome mean (MML = 0) 8.903 0.004 0.010 
N 73,725,046 73,725,046 73,725,046 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes 
 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.17: Subsample Analysis of the Effect of Medical Marijuana Laws on Birth Weight Across the Distribution 
 
 Birth weight (g) Extremely low birth weight 
(<1,000 g) 
Very low birth weight 
(<1,500 g) 
Low birth weight 
(<2,500 g) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
Panel A: Teenage mothers (Age < 20) 
MML 6.621** 
(2.658) 
7.691 
(4.999) 
2.666 
(3.652) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
-0.001* 
(0.000) 
-0.001 
(0.001) 
-0.001 
(0.001) 
-0.001 
(0.002) 
Outcome mean (MML = 0) 3,190.452 0.008 0.016 0.089 
N 9,973,650 9,973,650 9,973,650 9,973,650 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Panel B: Mothers with less than high school diploma (Age 20+) 
MML -3.675 
(3.476) 
2.371 
(4.087) 
5.084* 
(2.887) 
0.000 
(0.000) 
-0.000 
(0.000) 
-0.000 
(0.000) 
0.000 
(0.000) 
0.000 
(0.000) 
-0.000 
(0.000) 
0.001 
(0.001) 
0.002* 
(0.001) 
0.000 
(0.001) 
Outcome mean (MML = 0) 3,265.586 0.006 0.012 0.077 
N 13,032,825 13,032,825 13,032,825 13,032,825 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Panel C: Black mothers 
MML 21.321*** 
(5.463) 
0.410 
(8.654) 
-5.076 
(4.790) 
-0.001 
(0.000) 
-0.000 
(0.001) 
-0.000 
(0.000) 
-0.002 
(0.000) 
-0.000 
(0.001) 
-0.000 
(0.001) 
-0.007*** 
(0.002) 
0.000 
(0.003) 
0.002 
(0.002) 
Outcome mean (MML = 0) 3,126.878 0.014 0.025 0.114 
N 13,632,011 13,632,011 13,632,011 13,632,011 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.18: Subsample Analysis of the Effect of Medical Marijuana Laws on Gestation Across the Distribution 
 
 Gestation (weeks) Preterm 
(<37 weeks) 
Late preterm 
(34 – 36 weeks) 
Early term 
(37 – 38 weeks) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) 
Panel A: Teenage mothers (Age < 20) 
MML 0.022 
(0.014) 
0.009 
(0.012) 
0.002 
(0.009) 
-0.001 
(0.002) 
0.004*** 
(0.001) 
0.001 
(0.001) 
-0.002 
(0.001) 
0.002*** 
(0.001) 
0.000 
(0.001) 
-0.007*** 
(0.002) 
-0.005** 
(0.003) 
0.000 
(0.001) 
Outcome mean (MML = 0) 38.779 0.136 0.092 0.225 
N 9,898,205 9,898,205 9,898,205 9,898,205 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Panel B: Mothers with less than high school diploma (Age 20+) 
MML 0.019 
(0.018) 
0.017 
(0.013) 
-0.001 
(0.008) 
-0.003 
(0.002) 
0.004*** 
(0.002) 
0.000 
(0.001) 
-0.004*** 
(0.001) 
0.001 
(0.001) 
-0.000 
(0.001) 
-0.002 
(0.002) 
-0.007*** 
(0.002) 
-0.001 
(0.001) 
Outcome mean (MML = 0) 38.803 0.125 0.088 0.243 
N 12,895,286 12,895,286 12,895,286 12,895,286 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Panel C: Black mothers 
MML 0.029 
(0.018) 
-0.001 
(0.021) 
-0.030** 
(0.012) 
-0.002 
(0.002) 
0.005*** 
(0.001) 
0.003** 
(0.001) 
-0.002 
(0.002) 
0.002** 
(0.001) 
0.001 
(0.001) 
-0.008*** 
(0.003) 
-0.001 
(0.005) 
0.004 
(0.003) 
Outcome mean (MML = 0) 38.354 0.162 0.105 0.261 
N 13,576,850 13,576,850 13,576,850 13,576,850 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes No No Yes 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table 2.19: Subsample Analysis of the Effect of Medical Marijuana Laws on Apgar Scores Across the Distribution 
 
 5-Minute Apgar Score Severe Distress 
(Apgar Score 0 – 3) 
Mild Distress 
(Apgar Score 4 – 6) 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) 
Panel A: Teenage mothers (Age < 20) 
MML -0.083** 
(0.036) 
-0.098** 
(0.043) 
-0.069 
(0.052) 
0.002** 
(0.001) 
0.002* 
(0.001) 
0.001 
(0.001) 
0.005*** 
(0.002) 
0.005** 
(0.002) 
0.004 
(0.003) 
Outcome mean (MML = 0) 8.863 0.006 0.013 
N 8,185,893 8,185,893 8,185,893 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes 
Panel B: Mothers with less than high school diploma (Age 20+) 
MML -0.080** 
(0.353) 
-0.095* 
(0.047) 
-0.062 
(0.051) 
0.002 
(0.001) 
0.002** 
(0.001) 
0.001 
(0.001) 
0.004*** 
(0.001) 
0.004* 
(0.002) 
0.002 
(0.002) 
Outcome mean (MML = 0) 8.897 0.005 0.011 
N 9,597,685 9,597,685 9,597,685 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes 
Panel C: Black mothers 
MML -0.081** 
(0.039) 
-0.117** 
(0.047) 
-0.094 
(0.051) 
0.002* 
(0.001) 
0.003** 
(0.001) 
0.002** 
(0.001) 
0.006*** 
(0.002) 
0.007** 
(0.003) 
0.006* 
(0.003) 
Outcome mean (MML = 0) 8.820 0.009 0.015 
N 12,372,303 12,372,303 12,372,303 
State FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Individual-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-level controls Yes Yes Yes Yes Yes Yes Yes Yes Yes 
State-specific linear trends No Yes Yes No Yes Yes No Yes Yes 
State-specific quadratic trends No No Yes No No Yes No No Yes 
Notes: In every panel, each column represents a result from a separate regression. Robust standard errors are clustered at the state level and are in parentheses below OLS coefficients. 
Individual-level controls included but not shown: sex of infant, dummies for month of birth (February – December; January is the omitted category), dummies for live birth order (1 – 7; 8+ is 
the omitted category), age of mother, age of mother squared, indicator for Hispanic origin of mother, dummies for race of mother (Black, Native American/Alaskan Native, Asian/Pacific 
Islander; White is the omitted category), indicator for marital status of mother, dummies for education of mother (8th grade or less; some high school; some college; bachelor’s degree; 
master’s, doctorate, or professional degree; high school graduate is the omitted category). State-level controls included but not shown: marijuana decriminalization status, recreational 
marijuana legalization status, unemployment rate, state earned income tax credit program (EITC) status, whether the state EITC is refundable, generosity of the state EITC measured as a 
percentage of federal credit, minimum wage, and cigarette excise taxes. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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APPENDIX A: CONCEPTUAL FRAMEWORK 
 
Conceptual framework of Chapter 1 follows Rosenzweig and Schultz (1982, 1983). 
A family is assumed to derive utility from two types of goods – the health of its children, !, and consumer goods, ". Thus, the utility function of the family is: # = # !, " . 
Child health is affected by maternal malaria status during pregnancy '	(whether the 
mother had the disease and how severe it was), purchased or acquired market health inputs ) 
(such as antenatal care visits), family-specific exogenous health endowment * (due either to 
genetic or environmental conditions uninfluenced by parental behavior, but known to the 
family), and unobserved environmental factor + that can have heterogeneous effects on different 
individuals. This relationship is described by a health production function: ! = 	,(', ), *, +), ,/ ≠ 0, ,2 ≠ 0, ,3 ≠ 0, ,4 ≠ 0. 
Maternal malaria status is affected by malaria prevalence '5, malaria preventive 
measures 6, as well as an unobserved factor 7. This relationship is described by a malaria 
production function: ' = Γ('5, 6, 7). 
The family maximizes its utility function given the health production function and the 
malaria production function, which are assumed to be known, and subject to the budget 
constraint, given by the following equation: 
 88 
9 = "5:	+	)52 + 65<, 
where 9 is income and 5<, 52, 5< are the prices of the consumption goods, health inputs unrelated 
to malaria, and malaria preventive measures, respectively. 
This model assumes that health cannot be purchased directly. Other goods must be 
bought or utilized to influence health in a way described by the health production function. 
Specifically, child investment good ) is purchased only for the purpose of improving child 
health so that it enters the family utility function only through !. Another important assumption 
is that the family does not seek to optimize child health, but looks at child health as one utility-
augmenting good for which it must sacrifice other goods. Similarly, malaria preventive measures 
in pregnancy enter neither the utility function nor the child’s health production function directly, 
but only through the maternal malaria production function. 
Solving the household optimization problem allows to obtain demand functions for all 
health inputs () and 6) as well as health-neutral goods ": " = 	=:(5:, 52, 5<, 9, *, +, 7) , ) = 	=2(5:, 52, 5<, 9, *, +, 7) , 6 = 	=<(5:, 52, 5<, 9, *, +, 7) . 
From the demand functions and the expression >! = 	,/>' +	,2>) +	,3>* +	,4>+	, 
one can derive the effects of changes in the prices of the three types of goods on child health. It 
is easy to see that price effects on child health depend on the effects of changes in prices on the 
demand for health production inputs as well as on the marginal products of these inputs in the 
production of health. However, without additional restrictions, the model does not allow to make 
certain important predictions. Specifically, the model indicates that it is not sufficient to know 
the price effects of goods in order to predict how changes in prices will affect infant health. 
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Additionally, it is not clear how the environmental factor + can alter marginal products of inputs 
or biological processes underlying the health production function. Thus, estimating the 
parameters of the health production function is necessary for predicting and assessing effects of 
public policies. 
Using the expression for malaria production function, child health production function 
can be rewritten in the following way: ! = 	Ψ('5, 6, 7, ), *, +). 
For the purposes of this study, I am most interested in the relationship between malaria 
preventive measures 6 and child health !, @A@< . Providing empirical estimation of the relationship 
between antimalarial efforts and child health has important policy implications. Economic 
intuition does not provide a clear prediction with respect to the sign of the effect. While those 
pregnancies which would have ended in a live birth with or without antimalarial interventions, 
would have benefitted from the campaigns and resulted in healthier children (@A@< 	> 0), the 
pregnancies that would have ended in a miscarriage in the absence of campaigns, may now have 
resulted in a live birth, albeit the child health status may have been poor (@A@< 	< 0). 
Specifically, Chapter 1 provides an empirical estimation of the following health 
production function: !DEF = 	Ψ('5F, 6DEF, 7DEF, )DEF, *EF, +DEF), 
where !DEF is birth weight of the child G born to mother H in region I, '5F is malaria 
prevalence, 6 are health inputs which are bought or allocated only because they affect maternal 
malaria status, 7 is the unobserved environmental factor affecting maternal malaria, ) are 
consumer goods that can affect birth weight, * is a family-specific exogenous health endowment 
due either to genetic or environmental conditions uninfluenced by parental behavior, but known 
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to the family, and + is the environmental factor that can have heterogeneous effects on different 
children. 
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APPENDIX B: ADDITIONAL TABLES AND FIGURES 
 
Figure B1: Variation in Region-Level IPTp Coverage Across Countries, 2000–2013 
 
Notes: Underlying data from Demographic and Health Surveys. Region-level IPTp coverage represents proportion 
of pregnant women reporting receipt of at least one dose of intermittent preventive treatment in pregnancy (IPTp) 
with sulphadoxine-pyrimethamine.  
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Figure B1: Variation in Region-Level IPTp Coverage Across Countries in Sub-Saharan 
Africa, 2000–2013 (Continued) 
 
Notes: Underlying data from Demographic and Health Surveys. Region-level IPTp coverage represents proportion 
of pregnant women reporting receipt of at least one dose of intermittent preventive treatment in pregnancy (IPTp) 
with sulphadoxine-pyrimethamine. 
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Figure B2: Variation in Region-Level ITN Use Across Countries in Sub-Saharan Africa, 
2000–2013 
 
Notes: Underlying data from Malaria Atlas Project. Region level ITN use represents estimated proportion of 
individuals who slept under an insecticide-treated bed net (ITN) on any given night. 
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Figure B2: Variation in Region-Level ITN Use Across Countries in Sub-Saharan Africa, 
2000–2013 (Continued) 
 
Notes: Underlying data from Malaria Atlas Project. Region level ITN use represents estimated proportion of 
individuals who slept under an insecticide-treated bed net (ITN) on any given night.  
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Figure B3: Variation in Country-Level IRS Coverage in Sub-Saharan Africa, 2000–2013 
 
Notes: Underlying data from Malaria Atlas Project. IRS coverage represents estimated proportion of the population 
protected by indoor residual spraying (IRS) of insecticides. 
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Figure B3: Variation in Country-Level IRS Coverage in Sub-Saharan Africa, 2000–2013 
(Continued) 
 
Notes: Underlying data from Malaria Atlas Project. IRS coverage represents estimated proportion of the population 
protected by indoor residual spraying (IRS) of insecticides.  
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Figure B4: Variation in Country-Level ACT Coverage in Sub-Saharan Africa, 2000–2013 
 
Notes: Underlying data from Malaria Atlas Project. ACT coverage represents estimated proportion of cases of fever 
in under-5 year olds that were treated with artemisinin-based combination therapy (ACT). 
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Figure B4: Variation in Country-Level ACT Coverage in Sub-Saharan Africa, 2000–2013 
(Continued) 
 
Notes: Underlying data from Malaria Atlas Project. ACT coverage represents estimated proportion of cases of fever 
in under-5 year olds that were treated with artemisinin-based combination therapy (ACT). 
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Table B1: Estimated Effects of Antimalarial Interventions on Low Birth Weight 
Classification Assignment: Model Selection, All Children 
 
 (1) (2) (3) (4) (5) 
VARIABLES LBW LBW LBW LBW LBW 
Antimalarial interventions variables:      
IPTp-SP -0.010*** -0.010*** -0.010*** -0.010*** -0.010*** 
 (0.003) (0.003) (0.003) (0.003) (0.003) 
IPTp-SP x Malaria prevalence 0.006 0.006 0.005 0.001 0.001 
 (0.013) (0.013) (0.014) (0.014) (0.014) 
ITN 0.044*** 0.044*** 0.024 0.012 0.022 
 (0.012) (0.012) (0.026) (0.015) (0.024) 
ITN x Malaria prevalence -0.018 -0.016 -0.011 -0.203** -0.172 
 (0.051) (0.052) (0.081) (0.086) (0.118) 
IRS -0.002 -0.003 0.013 -0.005 0.002 
 (0.018) (0.019) (0.043) (0.016) (0.044) 
IRS x Malaria prevalence -0.045 -0.057 0.011 0.006 0.068 
 (0.099) (0.099) (0.112) (0.109) (0.108) 
ACT -0.011 -0.008 0.001 0.036 -0.009 
 (0.017) (0.017) (0.046) (0.027) (0.045) 
ACT x Malaria prevalence -0.172* -0.179* -0.141 -0.349* -0.243 
 (0.102) (0.103) (0.135) (0.180) (0.232) 
Other variables:      
Household in urban area 0.005** 0.005** 0.005* 0.005** 0.005** 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
Wealth quintile -0.006*** -0.006*** -0.006*** -0.006*** -0.006*** 
 (0.001) (0.001) (0.001) (0.001) (0.001) 
Mother has primary education -0.008*** -0.008*** -0.008*** -0.008*** -0.008*** 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
Mother has at least secondary education -0.016*** -0.016*** -0.016*** -0.017*** -0.017*** 
 (0.003) (0.003) (0.003) (0.003) (0.003) 
ANC visits: at most 3 -0.042*** -0.042*** -0.041*** -0.042*** -0.041*** 
 (0.009) (0.009) (0.009) (0.009) (0.009) 
ANC visits: 4 or more -0.059*** -0.059*** -0.058*** -0.058*** -0.058*** 
 (0.009) (0.009) (0.009) (0.009) (0.009) 
Mother's age at birth -0.000** -0.000** -0.000** -0.000** -0.000** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Male birth -0.023*** -0.024*** -0.024*** -0.023*** -0.023*** 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
First birth 0.047*** 0.047*** 0.048*** 0.048*** 0.048*** 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
Birth interval under 24 months 0.010*** 0.010*** 0.011*** 0.010*** 0.011*** 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
Constant 0.182*** 0.183*** 0.199*** 0.193*** 0.182*** 
 (0.012) (0.012) (0.027) (0.011) (0.028) 
      
Observations 143,131 143,131 143,131 143,131 143,131 
R-squared 0.022 0.024 0.025 0.027 0.029 
Region FE Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes 
Country x Month FE No Yes Yes Yes Yes 
Country x Year FE No No Yes No Yes 
Region x Trend No No No Yes Yes 
 
Notes: Robust standard errors are clustered at the region level, and are in parentheses below OLS coefficients. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table B2: Estimated Effects of Antimalarial Interventions on Small Size at Birth 
Classification Assignment: Model Selection, All Children 
 
 (1) (2) (3) (4) (5) 
VARIABLES Small Small Small Small Small 
Antimalarial interventions variables:      
IPTp-SP -0.014*** -0.014*** -0.013*** -0.015*** -0.013*** 
 (0.003) (0.003) (0.003) (0.003) (0.003) 
IPTp-SP x Malaria prevalence -0.016 -0.017 0.009 -0.002 0.000 
 (0.015) (0.015) (0.015) (0.014) (0.014) 
ITN -0.007 -0.014 -0.033 -0.031 -0.008 
 (0.017) (0.017) (0.037) (0.020) (0.027) 
ITN x Malaria prevalence 0.040 0.037 0.289** 0.188* 0.175 
 (0.074) (0.075) (0.114) (0.101) (0.145) 
IRS 0.006 0.010 -0.002 0.013 -0.014 
 (0.025) (0.026) (0.055) (0.017) (0.056) 
IRS x Malaria prevalence 0.078 0.090 -0.038 0.106 0.069 
 (0.091) (0.093) (0.152) (0.090) (0.144) 
ACT -0.062** -0.064** -0.030 -0.057** -0.030 
 (0.029) (0.029) (0.046) (0.028) (0.046) 
ACT x Malaria prevalence 0.015 0.010 -0.070 0.100 -0.189 
 (0.172) (0.173) (0.167) (0.188) (0.228) 
Other variables:      
Household in urban area 0.000 0.000 0.001 0.001 0.001 
 (0.003) (0.003) (0.003) (0.003) (0.003) 
Wealth quintile -0.007*** -0.007*** -0.007*** -0.007*** -0.007*** 
 (0.001) (0.001) (0.001) (0.001) (0.001) 
Mother has primary education -0.014*** -0.015*** -0.015*** -0.014*** -0.014*** 
 (0.003) (0.003) (0.003) (0.003) (0.003) 
Mother has at least secondary education -0.022*** -0.022*** -0.022*** -0.021*** -0.021*** 
 (0.004) (0.004) (0.004) (0.004) (0.004) 
ANC visits: at most 3 -0.033*** -0.033*** -0.034*** -0.034*** -0.035*** 
 (0.005) (0.005) (0.005) (0.004) (0.004) 
ANC visits: 4 or more -0.054*** -0.054*** -0.055*** -0.055*** -0.056*** 
 (0.005) (0.005) (0.004) (0.004) (0.004) 
Mother's age at birth 0.000 0.000 0.000 0.000 0.000 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Male birth -0.036*** -0.036*** -0.036*** -0.036*** -0.036*** 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
First birth 0.046*** 0.046*** 0.046*** 0.046*** 0.046*** 
 (0.003) (0.003) (0.003) (0.003) (0.003) 
Birth interval under 24 months 0.009*** 0.010*** 0.010*** 0.010*** 0.011*** 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
Constant 0.236*** 0.232*** 0.260*** 0.215*** 0.218*** 
 (0.009) (0.010) (0.023) (0.008) (0.021) 
      
Observations 277,245 277,245 277,245 277,245 277,245 
R-squared 0.045 0.045 0.047 0.050 0.052 
Region FE Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes 
Country x Month FE No Yes Yes Yes Yes 
Country x Year FE No No Yes No Yes 
Region x Trend No No No Yes Yes 
 
Notes: Robust standard errors are clustered at the region level, and are in parentheses below OLS coefficients. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table B3: Estimated Effects of Antimalarial Interventions on Very Small Size at Birth 
Classification Assignment: Model Selection, All Children 
 
 (1) (2) (3) (4) (5) 
VARIABLES Very small Very small Very small Very small Very small 
Antimalarial interventions variables:      
IPTp-SP -0.012*** -0.012*** -0.013*** -0.014*** -0.013*** 
 (0.002) (0.002) (0.003) (0.003) (0.003) 
IPTp-SP x Malaria prevalence 0.011 0.011 0.034** 0.028** 0.029** 
 (0.013) (0.012) (0.015) (0.013) (0.013) 
ITN 0.018* 0.016 -0.017 -0.004 0.022 
 (0.011) (0.011) (0.016) (0.010) (0.016) 
ITN x Malaria prevalence -0.122** -0.123* 0.072 0.045 0.033 
 (0.062) (0.062) (0.086) (0.046) (0.064) 
IRS 0.004 0.005 0.010 0.007 0.014 
 (0.014) (0.014) (0.022) (0.007) (0.020) 
IRS x Malaria prevalence 0.011 0.013 -0.139 0.056 0.009 
 (0.054) (0.055) (0.089) (0.047) (0.063) 
ACT -0.040* -0.040* -0.001 -0.008 0.003 
 (0.023) (0.023) (0.020) (0.018) (0.020) 
ACT x Malaria prevalence 0.030 0.033 -0.047 0.125 0.020 
 (0.122) (0.122) (0.126) (0.127) (0.128) 
Household in urban area -0.001 -0.001 -0.001 -0.001 -0.001 
 (0.002) (0.002) (0.002) (0.002) (0.002) 
Wealth quintile -0.003*** -0.003*** -0.003*** -0.003*** -0.003*** 
 (0.001) (0.001) (0.001) (0.001) (0.001) 
Mother has primary education -0.005*** -0.005*** -0.005*** -0.005*** -0.005*** 
 (0.001) (0.001) (0.001) (0.001) (0.001) 
Mother has at least secondary education -0.006*** -0.006*** -0.006*** -0.006*** -0.006*** 
 (0.002) (0.002) (0.001) (0.002) (0.002) 
ANC visits: at most 3 -0.020*** -0.020*** -0.019*** -0.018*** -0.019*** 
 (0.003) (0.003) (0.003) (0.003) (0.003) 
ANC visits: 4 or more -0.028*** -0.028*** -0.027*** -0.027*** -0.027*** 
 (0.003) (0.003) (0.003) (0.003) (0.003) 
Mother's age at birth 0.000*** 0.000*** 0.000*** 0.000*** 0.000*** 
 (0.000) (0.000) (0.000) (0.000) (0.000) 
Male birth -0.013*** -0.013*** -0.013*** -0.013*** -0.013*** 
 (0.001) (0.001) (0.001) (0.001) (0.001) 
First birth 0.019*** 0.019*** 0.019*** 0.019*** 0.019*** 
 (0.001) (0.001) (0.002) (0.001) (0.002) 
Birth interval under 24 months 0.006*** 0.006*** 0.006*** 0.006*** 0.006*** 
 (0.001) (0.001) (0.001) (0.001) (0.001) 
Constant 0.087*** 0.089*** 0.094*** 0.075*** 0.064*** 
 (0.006) (0.006) (0.010) (0.005) (0.008) 
      
Observations 277,245 277,245 277,245 277,245 277,245 
R-squared 0.035 0.035 0.038 0.042 0.043 
Region FE Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes 
Country x Month FE No Yes Yes Yes Yes 
Country x Year FE No No Yes No Yes 
Region x Trend No No No Yes Yes 
 
Notes: Robust standard errors are clustered at the region level, and are in parentheses below OLS coefficients. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Table B4: Estimated Effects of Antimalarial Interventions on Birth Weight: Model 
Selection, All Children 
 
 (1) (2) (3) (4) (5) 
VARIABLES Birth weight Birth weight Birth weight Birth weight Birth weight 
Antimalarial interventions variables:      
IPTp-SP -1.825 -1.904 -6.394 -0.727 -5.096 
 (6.301) (6.341) (6.459) (6.342) (6.524) 
IPTp-SP x Malaria prevalence -100.697*** -101.784*** -86.504*** -73.607** -79.315** 
 (30.976) (30.931) (31.080) (32.383) (32.953) 
ITN 29.563 29.768 -55.957 126.207*** -115.455* 
 (32.089) (32.644) (63.517) (38.049) (59.914) 
ITN x Malaria prevalence 291.969** 293.476** 138.597 347.382* 468.861* 
 (137.463) (136.191) (223.385) (197.097) (267.334) 
IRS -126.370** -130.582** 189.883** 62.289 191.530* 
 (52.036) (51.476) (92.477) (42.350) (97.422) 
IRS x Malaria prevalence -550.851*** -536.789*** -319.081 -91.926 -320.276 
 (196.455) (195.358) (264.038) (214.405) (264.232) 
ACT -185.051*** -183.811*** -153.459 20.569 -181.241 
 (50.387) (52.264) (122.405) (69.489) (121.337) 
ACT x Malaria prevalence -155.455 -126.439 -237.718 209.338 745.234 
 (309.611) (319.684) (372.001) (399.119) (500.163) 
Other variables:      
Household in urban area -16.568** -16.299** -15.563** -15.837** -16.100** 
 (7.673) (7.685) (7.677) (7.666) (7.732) 
Wealth quintile 6.824*** 6.739*** 6.240*** 6.096*** 6.087*** 
 (2.292) (2.293) (2.292) (2.277) (2.269) 
Mother has primary education 33.665*** 33.649*** 33.810*** 33.985*** 33.797*** 
 (6.369) (6.302) (6.396) (6.358) (6.407) 
Mother has at least secondary education 21.254*** 21.469*** 21.090*** 21.277*** 20.653*** 
 (6.883) (6.815) (6.799) (6.755) (6.769) 
ANC visits: at most 3 21.309 22.502 21.227 21.863 21.463 
 (21.723) (21.759) (21.684) (21.048) (21.263) 
ANC visits: 4 or more 82.310*** 83.695*** 80.940*** 83.685*** 81.386*** 
 (22.098) (22.136) (22.104) (21.319) (21.563) 
Mother's age at birth 1.623*** 1.605*** 1.480*** 1.652*** 1.483*** 
 (0.349) (0.351) (0.349) (0.348) (0.348) 
Male birth 115.550*** 115.497*** 115.512*** 115.230*** 115.237*** 
 (3.782) (3.817) (3.837) (3.840) (3.855) 
First birth -149.499*** -149.754*** -150.430*** -149.734*** -150.520*** 
 (5.526) (5.564) (5.561) (5.589) (5.571) 
Birth interval under 24 months -12.872** -13.329** -15.137** -13.565** -16.132*** 
 (5.886) (5.832) (5.882) (5.843) (5.872) 
Constant 3,105.719*** 3,102.348*** 3,158.142*** 3,121.799*** 3,148.886*** 
 (34.362) (34.195) (53.462) (29.507) (56.041) 
      
Observations 143,131 143,131 143,131 143,131 143,131 
R-squared 0.071 0.073 0.076 0.078 0.081 
Region FE Yes Yes Yes Yes Yes 
Year FE Yes Yes Yes Yes Yes 
Country x Month FE No Yes Yes Yes Yes 
Country x Year FE No No Yes No Yes 
Region x Trend No No No Yes Yes 
 
Notes: Robust standard errors are clustered at the region level, and are in parentheses below OLS coefficients. 
Asterisks denote statistical significance as follows: *** p-value £ 0.01, ** 0.01 £ p-value £ 0.05, * 0.05 < p-value £ 0.10.  
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Figure C1: U.S. Standard Certificate of Live Birth: 1989 Revision 
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Figure 4–A. U.S. Standard Certificate of Live Birth:  1989 Revision 
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Figure C1: U.S. Standard Certificate of Live Birth: 1989 Revision (Continued) 
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Figure 4–A. U.S. Standard Certificate of Live Birth:  1989 Revision - Con. 
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Figure C2: U.S. Standard Certificate of Live Birth: 2003 Revision 
  
U.S. STANDARD CERTIFICATE OF LIVE BIRTH 
LOCAL FILE NO.             BIRTH NUMBER:               
C H I L D  1.  CHILD’S NAME (First, Middle, Last, Suffix) 2.  TIME OF BIRTH                     (24 hr) 3. SEX  4.  DATE OF BIRTH (Mo/Day/Yr) 
 
 
 
 5. FACILITY NAME (If not institution, give street and number) 
 
 
 6. CITY, TOWN, OR LOCATION OF BIRTH 
 
 
 7.  COUNTY OF BIRTH 
M O T H E R  8a.  MOTHER’S CURRENT LEGAL NAME (First, Middle, Last, Suffix) 
 
8b.  DATE OF BIRTH (Mo/Day/Yr)  
 
  8c.  MOTHER’S NAME PRIOR TO FIRST MARRIAGE (First, Middle, Last, Suffix)  8d.  BIRTHPLACE (State, Territory, or Foreign Country)  
 
  9a. RESIDENCE OF MOTHER-STATE 
 
 9b.  COUNTY  9c.  CITY, TOWN, OR LOCATION 
  9d.  STREET AND NUMBER  9e.  APT. NO.  9f.  ZIP CODE  9g.  INSIDE CITY 
          LIMITS? 
 
     □   Yes   □  No 
F A T H E R  10a.  FATHER’S CURRENT LEGAL NAME (First, Middle, Last, Suffix) 
 
 10b.  DATE OF BIRTH (Mo/Day/Yr)   10c.  BIRTHPLACE (State, Territory, or Foreign Country)   
CERTIF IER  11.  CERTIFIER’S NAME:    _______________________________________________ 
 TITLE: □  MD    □   DO    □  HOSPITAL  ADMIN.   □ CNM/CM    □  OTHER MIDWIFE 
             □   OTHER (Specify)_____________________________ 
 12.  DATE CERTIFIED  
       ______/ ______ / __________ 
          MM       DD           YYYY 
 13.  DATE FILED BY REGISTRAR 
       ______/ ______ / __________ 
          MM       DD           YYYY 
INFORMATION FOR ADMINISTRATIVE USE 
M O T H E R 14.  MOTHER’S MAILING ADDRESS:     9 Same as residence, or:      State:                                                               City, Town, or Location:  
    Street & Number:                                                                                                                                                               Apartment No.:                                              Zip Code:  
 15. MOTHER MARRIED? (At birth, conception, or any time between)                                     □ Yes     □ No 
       IF NO, HAS PATERNITY ACKNOWLEDGEMENT BEEN SIGNED IN THE HOSPITAL?  □ Yes    □ No 
 16.  SOCIAL SECURITY NUMBER REQUESTED  
        FOR CHILD?        □  Yes   □  No 
 17.  FACILITY ID. (NPI)
 18.  MOTHER’S SOCIAL SECURITY NUMBER:                                                                         
 
19.  FATHER’S SOCIAL SECURITY NUMBER: 
                                                                          
INFORMATION FOR MEDICAL AND HEALTH PURPOSES ONLY 
M O T H E R  
 
20. MOTHER’S EDUCATION (Check the 
       box that best describes the highest 
       degree or level of school completed at 
       the time of delivery)  
 
  □   8th grade or less 
 
  □   9th - 12th grade, no diploma  
 
  □   High school graduate or GED 
         completed  
 
  □   Some college credit but no degree 
 
  □   Associate degree (e.g., AA, AS) 
 
  □   Bachelor’s degree (e.g., BA, AB, BS) 
 
□   Master’s degree (e.g., MA, MS,   
       MEng,  MEd, MSW, MBA) 
 
  □  Doctorate (e.g., PhD, EdD) or 
        Professional degree (e.g., MD, DDS, 
        DVM, LLB, JD) 
 
21.  MOTHER OF HISPANIC ORIGIN?  (Check  
       the box that best describes whether the  
       mother is Spanish/Hispanic/Latina. Check the  
       “No” box if  mother is not Spanish/Hispanic/Latina) 
 
  □   No, not Spanish/Hispanic/Latina 
 
  □   Yes, Mexican, Mexican American, Chicana 
 
  □   Yes, Puerto Rican 
 
  □   Yes, Cuban 
 
  □   Yes, other Spanish/Hispanic/Latina 
 
     (Specify)_____________________________ 
 
22.  MOTHER’S RACE (Check one or more races to indicate  
       what the mother  considers herself  to be) 
  □    White 
  □   Black or African American 
  □   American Indian or Alaska Native  
        (Name of the enrolled or principal tribe)________________ 
  □   Asian Indian 
  □  Chinese 
  □  Filipino 
  □  Japanese 
  □  Korean 
   □  Vietnamese  
  □  Other Asian (Specify)______________________________ 
  □  Native Hawaiian 
  □  Guamanian or Chamorro 
  □  Samoan 
  □  Other Pacific Islander (Specify)______________________ 
  □  Other (Specify)___________________________________ 
 
F A T H E R 
M
ot
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r’s
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e 
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__
__
__
__
__
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__
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23. FATHER’S EDUCATION (Check the 
       box that best describes the highest 
       degree or level of school completed at 
       the time of delivery)  
 
  □   8th grade or less 
 
   □    9th - 12th grade, no diploma  
 
  □   High school graduate or GED 
         completed  
 
  □   Some college credit but no degree 
 
  □   Associate degree (e.g., AA, AS) 
 
  □   Bachelor’s degree (e.g., BA, AB, BS) 
 
□   Master’s degree (e.g., MA, MS,   
      MEng,  MEd, MSW, MBA) 
 
  □  Doctorate (e.g., PhD, EdD) or 
        Professional degree (e.g., MD, DDS, 
        DVM, LLB, JD) 
 
 
24.  FATHER OF HISPANIC ORIGIN?  (Check  
       the box that best describes whether the  
       father is Spanish/Hispanic/Latino.  Check the  
       “No” box if  father is not Spanish/Hispanic/Latino) 
 
  □   No, not Spanish/Hispanic/Latino 
 
  □   Yes, Mexican, Mexican American, Chicano 
 
  □   Yes, Puerto Rican 
 
  □   Yes, Cuban 
 
  □   Yes, other Spanish/Hispanic/Latino 
 
     (Specify)_____________________________ 
 
25.  FATHER’S RACE (Check one or more races to indicate  
       what the father  considers himself to be) 
 
  □    White 
  □   Black or African American 
  □   American Indian or Alaska Native  
        (Name of the enrolled or principal tribe)________________ 
  □   Asian Indian 
  □  Chinese 
  □  Filipino 
  □  Japanese 
  □  Korean 
   □ Vietnamese  
  □  Other Asian (Specify)______________________________ 
  □  Native Hawaiian 
  □  Guamanian or Chamorro 
  □  Samoan 
  □  Other Pacific Islander (Specify)______________________ 
  □  Other (Specify)___________________________________ 
  26.  PLACE WHERE BIRTH OCCURRED (Check one) 
 □  Hospital 
 □  Freestanding birthing center 
 □  Home Birth: Planned to deliver at home? 9 Yes  9 No 
 □  Clinic/Doctor’s office  
 □  Other (Specify)_______________________ 
 
 27.   ATTENDANT’S NAME, TITLE, AND NPI 
 
 NAME: _______________________  NPI:_______ 
 
 TITLE:  □  MD  □  DO  □  CNM/CM   □  OTHER MIDWIFE 
      □  OTHER (Specify)___________________ 
 
 28. MOTHER TRANSFERRED FOR MATERNAL  
       MEDICAL OR FETAL INDICATIONS FOR  
       DELIVERY?   □  Yes   □   No 
       IF YES, ENTER NAME OF FACILITY MOTHER  
       TRANSFERRED FROM:          
        
        _______________________________________ 
REV. 11/2003 
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Figure C2: U.S. Standard Certificate of Live Birth: 2003 Revision (Continued) 
  
 
MOTHER  29a.  DATE OF FIRST PRENATAL CARE VISIT   ______ /________/ __________    □  No Prenatal Care 
     M M        D D              YYYY  
 29b.  DATE OF LAST PRENATAL CARE VISIT 
          ______ /________/ __________  
           M M        D D              YYYY  
30.  TOTAL NUMBER OF PRENATAL VISITS FOR THIS PREGNANCY 
 
         _________________________ (If none, enter A0".) 
 31.  MOTHER’S HEIGHT 
         _______  (feet/inches) 
32. MOTHER’S PREPREGNANCY WEIGHT  
         _________ (pounds)  
33.  MOTHER’S WEIGHT  AT DELIVERY 
         _________ (pounds)      
34. DID MOTHER GET WIC FOOD FOR HERSELF 
       DURING THIS PREGNANCY? □  Yes   □  No 
35.  NUMBER OF PREVIOUS 
       LIVE BIRTHS (Do not include 
        this child) 
 
36. NUMBER OF OTHER 
       PREGNANCY OUTCOMES  
       (spontaneous or induced  
       losses or ectopic pregnancies)
 35a.  Now Living 
 
 Number _____ 
 
 □  None 
 
35b. Now Dead 
 
Number _____ 
 
 □  None 
 
36a.  Other Outcomes  
    
  Number  _____  
 
  □  None 
37. CIGARETTE SMOKING BEFORE AND DURING PREGNANCY 
       For each time period, enter either the number of cigarettes or the 
       number of packs of cigarettes smoked.   IF NONE, ENTER A0". 
 
   Average number of cigarettes or packs of cigarettes smoked per day. 
                                                            # of cigarettes            # of packs 
    Three Months Before Pregnancy       _________     OR     ________ 
    First Three  Months of Pregnancy      _________    OR     ________ 
    Second Three Months of Pregnancy  _________    OR     ________ 
    Third Trimester of Pregnancy             _________    OR     ________ 
38.  PRINCIPAL SOURCE OF 
        PAYMENT FOR THIS 
        DELIVERY 
 
  □  Private Insurance 
  □  Medicaid 
  □  Self-pay 
  □  Other 
     (Specify) _______________ 
 
 
 
 35c.  DATE OF LAST LIVE BIRTH  
          _______/________ 
             MM        Y Y Y Y 
36b.  DATE OF LAST OTHER 
         PREGNANCY OUTCOME 
          _______/________ 
             MM        Y Y Y Y 
 39.  DATE  LAST NORMAL MENSES  BEGAN 
          ______ /________/ __________  
           M M        D D              YYYY  
 
 40. MOTHER’S MEDICAL RECORD NUMBER   
 
 
MEDICAL 
AND 
HEALTH 
INFORMATION 
43.  OBSTETRIC PROCEDURES (Check all that apply) 
 
  □  Cervical cerclage 
  □  Tocolysis 
 
  External cephalic version: 
     □  Successful 
     □  Failed 
 
  □  None of the above 
 
44.  ONSET OF LABOR (Check all that apply) 
 
 □  Premature Rupture of the Membranes (prolonged, ∃12 hrs.) 
  
 □  Precipitous Labor (<3 hrs.) 
  
 □  Prolonged Labor (∃ 20 hrs.) 
 
 □  None of the above 
 
46.  METHOD OF DELIVERY 
 
 A.  Was delivery with forceps attempted but 
       unsuccessful? 
            □  Yes   □  No 
 
 B. Was delivery with vacuum extraction attempted 
       but unsuccessful? 
            □  Yes    □  No 
 
 C.  Fetal presentation at birth  
        □   Cephalic   
        □   Breech 
        □   Other 
 
 D. Final route and method of delivery (Check one) 
        □  Vaginal/Spontaneous 
        □  Vaginal/Forceps 
        □  Vaginal/Vacuum   
        □  Cesarean   
            If cesarean, was a trial of labor attempted? 
             □  Yes 
             □  No 
41.  RISK FACTORS IN THIS PREGNANCY 
                 (Check all that apply) 
  Diabetes 
       □   Prepregnancy  (Diagnosis prior to this pregnancy) 
       □   Gestational      (Diagnosis in this pregnancy) 
 
  Hypertension 
       □   Prepregnancy   (Chronic) 
       □   Gestational  (PIH, preeclampsia) 
       □   Eclampsia 
   
  □  Previous preterm birth 
 
  □  Other previous poor pregnancy outcome (Includes 
       perinatal death, small-for-gestational age/intrauterine 
       growth restricted birth) 
 
  □   Pregnancy resulted from infertility treatment-If yes, 
        check all that apply: 
       □    Fertility-enhancing drugs, Artificial insemination or  
              Intrauterine insemination 
       □   Assisted reproductive technology (e.g., in vitro 
            fertilization (IVF), gamete intrafallopian 
            transfer  (GIFT)) 
 
  □   Mother had a previous cesarean delivery 
            If yes, how many __________ 
 
  □   None of the above 
 
 
 
 
 
 
 
 
 
 
42.  INFECTIONS PRESENT AND/OR TREATED 
       DURING THIS  PREGNANCY (Check all that apply) 
 
   □   Gonorrhea 
   □   Syphilis    
   □   Chlamydia 
   □   Hepatitis B 
   □   Hepatitis C 
   □   None of the above 
 
 
 
45.  CHARACTERISTICS OF LABOR AND DELIVERY 
                          (Check all that  apply) 
 
  □   Induction of labor 
  □   Augmentation of labor 
  □   Non-vertex presentation 
  □   Steroids (glucocorticoids) for fetal lung maturation 
        received by the mother prior to delivery 
  □   Antibiotics received by the mother during labor 
  □   Clinical chorioamnionitis diagnosed during labor or 
         maternal  temperature >38°C (100.4°F) 
  □   Moderate/heavy meconium staining of the amniotic fluid 
  □   Fetal intolerance of labor such that one or more of the 
         following actions was taken:  in-utero resuscitative 
         measures, further fetal assessment, or operative delivery 
  □   Epidural or spinal anesthesia during labor 
  □   None of the above 
47.  MATERNAL MORBIDITY (Check all that apply) 
     (Complications associated with labor and 
      delivery) 
  □    Maternal transfusion 
  □    Third or fourth degree perineal laceration 
  □    Ruptured uterus 
  □    Unplanned hysterectomy 
  □    Admission to intensive care unit 
  □    Unplanned operating room procedure 
         following delivery 
  □    None of the above 
 
 
NEWBORN INFORMATION 
48.  NEWBORN MEDICAL RECORD NUMBER 
 NEWBORN 
49.  BIRTHWEIGHT (grams preferred, specify unit) 
 
             ______________________ 
                   9 grams     9 lb/oz  
50.  OBSTETRIC ESTIMATE OF GESTATION: 
 
     _________________  (completed weeks) 
51.  APGAR SCORE: 
 Score at 5 minutes:________________________ 
   If 5 minute score is less than 6, 
 
 Score at 10 minutes: _______________________ 
 
52. PLURALITY - Single, Twin, Triplet, etc. 
 
 (Specify)________________________ 
 53.  IF NOT SINGLE BIRTH - Born First, Second, 
 
        Third, etc. (Specify) ________________ 
 
 
54.  ABNORMAL CONDITIONS OF THE NEWBORN 
                           (Check all that apply) 
 
 □   Assisted ventilation required immediately 
       following delivery 
 
 □   Assisted ventilation required for more than 
       six hours 
 
 □   NICU admission 
 
 □   Newborn given surfactant replacement 
       therapy 
 
 □   Antibiotics received by the newborn for 
       suspected neonatal sepsis 
 
 □   Seizure or serious neurologic dysfunction 
 
 □   Significant birth injury (skeletal fracture(s), peripheral  
       nerve  injury, and/or soft tissue/solid organ hemorrhage  
       which  requires intervention) 
 
 
 9  None of the above 
 
55.  CONGENITAL ANOMALIES OF THE NEWBORN 
                         (Check all that apply) 
  □   Anencephaly 
  □   Meningomyelocele/Spina bifida 
  □   Cyanotic congenital heart disease         
  □   Congenital diaphragmatic hernia          
  □   Omphalocele 
  □   Gastroschisis 
  □   Limb reduction defect (excluding congenital  
        amputation and dwarfing syndromes)                  
  □   Cleft Lip with or without Cleft Palate 
  □   Cleft Palate alone 
  □   Down Syndrome 
         □   Karyotype confirmed 
         □   Karyotype pending 
  □    Suspected chromosomal disorder          
         □   Karyotype confirmed 
         □   Karyotype pending 
  □    Hypospadias      
  □    None of the anomalies listed above   
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56.  WAS INFANT TRANSFERRED WITHIN 24 HOURS OF DELIVERY?   9  Yes  9  No 
      IF YES, NAME OF FACILITY INFANT TRANSFERRED                
TO:______________________________________________________ 
57.  IS INFANT LIVING AT TIME OF REPORT? 
 □  Yes  □  No   □  Infant transferred, status unknown 
58. IS THE INFANT BEING 
      BREASTFED AT DISCHARGE? 
           □   Yes  □   No 
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Table C1: Implementation of the 2003 U.S. Standard Certificate of Live Birth, 2003–2013 
 
Year 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 
Total 42 
states 
and DC 
39 
states 
and DC 
38 
states 
and DC 
35 
states 
and DC 
30 
states 
27 
states 
24 
states 
19 
states 
13 
states 
9 states 2 states 
Alabama            
Alaska X           
Arizona            
Arkansas            
California X X X X X X X X    
Colorado X X X X X X X     
Connecticut            
Delaware X X X X X X X X    
District of 
Columbia 
X X X X X       
Florida X X X X X X X X X X  
Georgia X X X X X X X     
Hawaii            
Idaho X X X X X X X X X X  
Illinois X X X X        
Indiana X X X X X X X     
Iowa X X X X X X X     
Kansas X X X X X X X X X   
Kentucky X X X X X X X X X X  
Louisiana X X X X        
Maine X           
Maryland X X X X        
Massachusetts X X X         
Michigan X X X X X X X     
Minnesota X X X         
Mississippi X           
Missouri X X X X        
Montana X X X X X X      
Nebraska X X X X X X X X X   
Nevada X X X X X       
New 
Hampshire 
X X X X X X X X X X  
New Jersey            
New Mexico X X X X X X      
New York 
(excluding 
NYC) 
X X X X X X X X X X  
New York 
City 
X X X X X X      
North 
Carolina 
X X X X        
North Dakota X X X X X X X X    
Ohio X X X X X X X X    
Oklahoma X X X X X       
Oregon X X X X X X      
Pennsylvania X X X X X X X X X X X 
Rhode Island            
South 
Carolina 
X X X X X X X X X X  
South Dakota X X X X X X X X    
Tennessee X X X X X X X X X X  
Texas X X X X X X X X X   
Utah X X X X X       
Vermont X X X X X X X X X   
Virginia X X          
Washington X X X X X X X X X X X 
West Virginia            
Wisconsin X X X         
Wyoming X X X X X X X X    
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